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 Part 1 Introduction 
 
Coronary artery disease (CAD) is a multifactorial and complex condition resulting from the 
interaction between genes and environmental factors. In the last decades several studies 
have tried to identify major cardiovascular risk factors, therapies and preventive measures in 
order to fight against this common and severe disease. Statin treatment plays a central role 
in the prevention of cardiovascular disease, in fact, in addition to their impact on cholesterol 
levels, statins have shown multiple non lipid-lowering pleiotropic effects such as anti-
oxidant, anti-inflammatory and anti-thrombotic properties with enhancement of endothelial 
nitric oxide production and reducing of endothelin secretion (1-3). Therefore, they are 
highly recommended both as chronic therapy in patients with CAD, but also with a loading 
dose in the early phase of acute coronary syndrome to stabilize the plaque and reduce acute 
complication, especially if a percutaneous coronary intervention (PCI) is performed. 
Genetics plays an important role in determining the inherent CAD vulnerability and in 
affecting the response and potentially the beneficial effects of statin therapy.                                                                                                        
Contrast-induced nephropathy (CIN) is a common complication of procedures that foresee 
the use of contrast media and is known as the third leading cause of hospital-acquired acute 
kidney injury, accounting for 11% of all cases (4). In last decades several therapies for the 
prevention of CIN, such as different hydration and alkalinization measures (5,6), N-
acetylcysteine (NAC) (7), Fenoldopam, hemodyalisis and hemofiltration (8,9) have been 
explored in randomized clinical trial with conflicting results. Due to the important 
pleiotropics effect of statins, a large number of studies have assessed their role for the 
prevention of CIN. Recent studies (10,11) showed a protective effect of statin therapy in 
 patients treated before coronary angiography/PCI, while other studies suggested that statin 
therapy is not useful for the prevention of CIN (12,13).                                               
Kinesis-Like Protein 6 (KIF 6) is an omodimeric protein expressed in coronary arteries and 
other vascular tissues, that is involved in cellular microtubular transport (14). The impact of 
KIF 6 gene on cardiovascular risk modulation has been investigated since 2007 due to the 
presence of a single nucleotide polymorphism (non synonym replacement A>G) related 
with the replacement of Trp 719 with arginine (Arg). Several prospective trials and meta-
analysis (15-17) assessed the association between this genetic variant (expressed in 60% of 
European population) and a significant increase of cardiovascular risk, anyway these results 
were not confirmed in a large study (Heart Protection study that involved more than 18000 
patients (18). Several mechanism such as a modification in the particles binding capacity 
(19), a modulation in the endothelial cells progenitors growth (20) and an increased 
expression of KIF 6 in the population with the risk allele (21) has been proposed to explain 
this association. Particular attention in last years has been focused on the role of the 
Trp719ARg polymorphism in the modulation of response to statin treatment. Several 
clinical trials showed a significant association between anti-inflammatory, metabolics and 
vasoprotective effects of statin therapy and a reduction in cardiovascular events in the 
population with the risk allele (22,23). Moreover these protective effects with a significant 
reduction (about 13%) of LDL-cholesterol level and risk of cardiovascular events of statin 
therapy has been recently confirmed by two meta-analysis (24,25).  
Therefore, the aim of the current thesis was to identify new prognostic factor for 
cardiovascular risk assessment and the risk of contrast induced nephropathy, with a special 
 focus on the association between of KIF-6 polymorphism (Trp719Arg polymorphism)  and 
the prevalence and extent of CAD, the occurrence of CIN and modulation of the protective 
effects of statin therapy. 
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Abstract 
Background. Serum uric acid (SUA) elevation has been largely addressed in the past as a 
possible risk factor for cardiovascular disease. However, uric acid has not clearly emerged 
as independent risk factor for coronary artery disease. Several studies in literature have 
assessed sex-related differences in the association between elevated SUA levels and 
cardiovascular events with conflicting results. Therefore, aim of the current study was to 
evaluate the relationship between uric acid levels and the extent of coronary artery disease 
in male and female patients undergoing coronary angiography. 
Methods. Our population is represented by 3520 consecutive patients undergoing coronary 
angiography from March 2007 to October 2012. Patients were divided according to Tertiles 
of SUA (Males, Group 1, < 5.5mg/dL-0.33mmol/mol, n=762, Group 2, 5.5-6.8mg/dL–0.33-
0.40mmol/mol, n=829 and Group 3 > 6.8mg/dL-0.40mmol/mol, n=851), (Females, Group 
1, < 4.8mg/dL-0.28mmol/mol, n=349, Group 2, 4.8-6.3mg/dL–0.28-0.37mmol/mol, n=359 
and Group 3 > 6.3mg/dL-0.37mmol/mol, n=370). Fasting samples were collected for uric 
acid levels assessment. Coronary disease was defined for at least 1 vessel stenosis > 50% as 
 evaluated by QCA. Severe coronary disease was defined as three-vessel disease and/or left 
main disease. 
Results. Among 3520 patients, we identified 2442 men (69.4%) and 1078 women (30.6%). 
Males had higher levels of uric acid than women (6.33 + 1.7 vs 5.8 + 1.9 - p<0.001). The 
association between elevated uric acid (≥ 7 mg/dl or 0.42 mmol/l) and male gender was 
confirmed after correction for baseline confounding factors (Adjusted OR=1.28 [1.01-1.62], 
p=0.004). Males displayed a significantly higher prevalence and extent of CAD (p<0.001) 
and more complex coronary lesions (p<0.001). However, no significant relationship was 
observed between uric acid and CAD (Adjusted OR [95%CI] = 0.90 [0.76-1.06], p = 0.22) 
or severe CAD (Adjusted OR [95%CI] = 0.89 [0.79-1.01], p = 0.08). Among females, 
higher SUA levels were significantly associated with higher prevalence of severe CAD 
(p<0.001) (Adjusted OR [95%CI] = 1.29 [1.03-1.62], p = 0.03). 
Conclusion. Our study showed that uric acid levels are significantly higher in men. 
However, high uric acid levels are associated with severe CAD only in women. Future large 
studies are certainly needed to confirm our findings and to evaluate the effects of SUA 
lowering therapies on cardiovascular prevention and outcome, especially in women.  
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 Introduction 
Coronary artery disease (CAD) still represents the leading cause of death in developed 
countries (1,2). The improvement in pharmacological therapies and percutaneous 
revascularization procedures have greatly contributed to the relevant reduction in mortality 
observed in the last decades for coronary artery disease, particularly in the setting of acute 
myocardial infarction (3-5), however, the results are still unsatisfactory in high-risk 
subgroups such as patients with diabetes or with impaired renal function (6,7). Therefore, 
large interests have been focused on the identification of new risk factors for CAD and its 
prevention.  
Serum uric acid (SUA), a degradation metabolite of purines, has been addressed in the past 
as a possible risk factor for cardiovascular disease (8,9) on the basis that hyperuricemia 
could induce atherosclerosis progression increasing oxidative stress and endothelial 
dysfunction (10,11). However, in the last decades several studies have assessed the role of 
SUA as a risk factor for CAD with conflicting results. We previously found no association 
between uric acid and the extent of CAD (12). However, even though it is well know that 
SUA levels are lower in women than in men (13), some, but not all studies, have reported an  
association between SUA, cardiovascular events and CAD related mortality only in women. 
Plausible explanation for such a mechanism is still lacking (14,15).  
Therefore, aim of the current study was to evaluate the relationship between uric acid levels 
and the extent of coronary artery disease in male and female patients undergoing coronary 
angiography. 
 
 
 Methods 
Our population is represented by 3520 consecutive patients undergoing coronary 
angiography at Catheterization Laboratory of AOU “Maggiore della Carità”, Novara, from 
March 2007 to October 2012. 
All demographic and clinical data were collected after obtaining written informed consent 
from the patient and included in a dedicated database, in adherence to rules for protection of 
human subjects. No exclusion criteria were applied. Hypertension was defined as systolic 
pressure > 140 mmHg and/or diastolic pressure > 90 mmHg or if the individual was taking 
an antihypertensive medication. The diagnosis of diabetes was based on previous history of 
diabetes treated with or without drug therapies, fasting glycaemia > 126 mg/dL, random 
glycaemia > 200 mg/dL or HbA1c > 6.5%. ACS was defined as an elevation of cardiac 
biomarkers beyond the upper limit of normal (ULN) (respectively 0,04 µg/l for Troponin I 
and 5,00 µg/l for CK-MB) due to angiographically documented critical coronary stenosis 
(>70%). Hyperuricemia was defined as SUA levels >7mg/dL or 0.42mmol/mol. 
Biochemical measurements                                            
Blood samples were drawn at admission in patients undergoing elective (following a fasting 
period of 12 h) or urgent coronary angiography. Glucose, creatinine, uric acid, blood cells 
count and lipid profile were determined by standard methods. Cardiac biomerakers 
(Troponin I and CK-MB) were assessed by sandwich immunoassay with direct 
chemiluminescence. 
Coronary angiography                                                  
Coronary angiography was routinely performed, preferring a radial approach, using 6-
French right and left heart catheters. Quantitative coronary angiography was performed by 
 experienced interventional cardiologists by automatic edge-detection systems (Siemens 
Acom Quantcor QCA, Erlangen, Germany) as previously described (16). After the visual 
inspection of the coronary artery, the frame of optimal clarity was selected, showing lesion 
at maximal narrowing and arterial silhouette in sharpest focus. After the calibration of 
guiding catheter, analysed arterial segment with coronary lesion was defined by moving the 
cursor from the proximal to the distal part of coronary artery to ensure adequate 
determination of reference diameter. We have measured minimal luminal diameter, 
reference diameter, percent diameter stenosis, and length of the lesion. 
Significant coronary artery disease was defined as at least 1 coronary stenosis more than 
50%. Severe coronary disease was defined as three-vessel disease and/or left main disease. 
For patients who had previously undergone a percutaneous coronary intervention, even 
though no restenosis was observed, the treated vessel was considered as significantly 
diseased. In previously bypassed patients, native arteries and grafts were taken into account 
in the evaluation of extension of artery disease (number of diseased vessels). 
 
Statistical analysis                                     
Continuous data were expressed as mean + SD and categorical data as percentage. Analysis 
of variance and chi-square test were used for continuous and categorical variables, 
respectively. A trend analysis was performed across tertiles of SUA according to sex (17). 
The relationship between uric acid and coronary artery disease was evaluated at multivariate 
analysis separately in males and females after correction for baseline confounding factors 
that were entered in the model in block for each analysis. Results were considered 
 statistically significant at two-sided p< 0.05. Statistical analysis was performed using the 
SPSS 17.0 statistical package.  
 
Table 1. Clinical and demographical characteristics according to sex.  
Baseline Clinical Characteristics  
 
Female 
(n=1078) 
Male 
(n=2442) 
P value 
Arterial hypertension (%)  75.3 69.7 0.001 
Age (Mean +-SD) 70.8+/-10.6 66.2+/-11.3 <0.001 
Smokers (%)    <0.001 
Active smokers 15.8 31.7  
Previous smokers 8.0 24.1  
Dyslipidemia ( %) 55.3 55.9 0.73 
Diabetes (%) 37.3 36.8 0.77 
Family history of CAD (%) 27.8 28.9 0.51 
History of MI (%)  15.7 28.5 <0.001 
Previous PCI (%)  16.1 27.3 <0.001 
Previous CABG (%) 6.4 14.3 <0.001 
Previous Stroke (%) 4 7.9 <0.001 
Renal failure (%) 39.2 23.4 <0.001 
Indication for angiography p<0.001 
Stable angina or silent ischemia (%) 19.2 25.7  
Acute Coronary Syndrome (%) 60.4 57.4  
DCM or valvular disease (%) 20.4 17  
Biochemistry    
White blood cells (10^3/µl) 7.64+/-2.5 8.01+/-3.1 0.001 
Platelets Count (10^5/ml) 237.3+/-72.4 206.9+/-60.3 <0.001 
Haemoglobin (g/dl) 12.4+/-1.5 13.8+/-1.6 <0.001 
Creatinine (mg/dl) 0.98+/-0.4 1.01+/-0.36 <0.001 
Glycaemia (mg/dl) 126.3+/-54.7 124.6+/-48.8 0.35 
Glycosylated Haemoglobin (%) 6.3+/-1.3 6.2+/-1.3 0.08 
Total cholesterol (mg/dL) 170.1+/-43.5 160.7+/-40.5 <0.001 
Tryglicerides (mg/dL) 125.9+/-67.7 137.7+/-85 <0.001 
HDL cholesterol 44.7+/-13.6 39.4+/-11.6 <0.001 
LDL cholesterol 104.5+/-41.6 100.5+/-46 0.01 
Reactive protein C (mg/dL) 1.53+/-3.1 1.25+/-2.6 0.009 
Uric Acid (mg/dl) 5.8+/-1.9 6.3+/-1.7 <0.001 
Fibrinogen (mg/dL) 464.4+/-143.1 429+/-152.6 <0.001 
Therapy at admission    
ACE inhibitors (%) 35.5 39.1 0.04 
ARB (%) 24.5 18.5 <0.001 
 Nitrate (%) 35.6 35.7 0.94 
Beta blockers (%) 50.8 51 0.95 
Calcium antagonists (%) 20.1 20.2 0.93 
Diuretics (%) 36.3 27.7 <0.001 
Statins (%) 41.8 50.9 <0.001 
ASA (%) 52.9 59.8 <0.001 
Clopidogrel (%) 21.6 23.7 0.17 
Table 2. Angiographic characteristics (per lesion) according to sex. 
Variable  Female 
(n=3528) 
Male 
(n=8054) 
P value 
Coronary artery disease (%)§ 65.1 81.5 <0.001 
Left main/trivessel disease (%)§ 21.5 32 <0.001 
Left main coronary (%)§ 7.6 10.1 0.02 
Left anterior descending coronary 
(%)§ 
45.4 56.3 <0.001 
Circumflex coronary (%)§ 30.7 45 <0.001 
Anterolateral branch (%) § 5.5 8.8 0.002 
Right  coronary(%)§ 35.7 50 <0.001 
Complex type C lesions (%) 27.5 37.1 <0.001 
Proximal vessel tortuosity (%) 3.6 3.6 0.952 
Spontaneous dissection (%) 0.5 0.4 0.492 
Lesion lenght (mm) 18.43  11.57 20.39  13.12 <0.001 
Vessel diameter (mm) 2.88  0.76 2.97  1.24 0.014 
Stenosis %(mean SD) 85.0  15.2 86.9  14.7 <0.001 
Calcified lesions(%) 24.2 24.2 0.976 
Bifurcation (%) 22 21.5 0.654 
Intracoronary Thrombus (%) 4.4 5.8 0.05 
In-stent Restenosis (%) 3.4 4.5 0.067 
TIMI flow   <0.001 
         3 (%) 76.2 68.3  
         2 (%) 4.8 5  
         1 (%) 2.6 3.2  
         0 (%) 16.4 23.5  
 
Results  
Among 3520 patients undergoing coronary angiography, we identified 2442 men (69.4%) 
and 1078 women (30.6%). Main demographic and clinical characteristics in females and 
males are listed in Table 1. 
Males were younger (p<0.001), smokers (p<0.001) with previous history of myocardial 
infarction (p<0.001), previous PCI (p<0.001), CABG (p<0.001) and cerebrovascular 
 accident (p<0.001), but with lower prevalence of hypertension (p=0.001) and renal failure 
(p<0.001). Male sex was related to higher haemoglobin (p<0.001), white blood cells 
(p=0.001), creatinine (p<0.001) and tryglicerides (p<0.001), but lower platelets count 
(p<0.001), total cholesterol (p<0.001), HDL-cholesterol (p<0.001), LDL-cholesterol 
(p=0.01), reactive protein C (p=0.009) and fibrinogen (p<0.001). Males were more often on 
therapy with angiotensin coverting enzyme (ACE) inhibitors (p=0.04), statins (p<0.001) and 
ASA (p<0.001), but less often with angiotensin II receptor blockers (ARBs) (p<0.001) and 
diuretics (p<0.001) at admission. Stable angina or silent ischemia was more often related to 
male sex as indication for angiography (p<0.001). Males had higher levels of uric acid than 
women (6.33 + 1.7 vs 5.8 + 1.9 - p<0.001) (Figure 1).  
The association between elevated uric acid (≥ 7 mg/dl or 0.42 mmol/l) and male gender was 
confirmed after correction for baseline confounding factors (hypertension, age, smoke, renal 
failure,  previous AMI, previous PCI, previous CABG, previous stroke, indication for 
angiography, platelets count, white blood cells, haemoglobin, basal creatinine, total 
cholesterol, LDL cholesterol, HDL cholesterol, tryglycerides, fibrinogen, reactive C protein, 
therapy with ARB, ACE inhibitors, diuretics, ASA and statins); Adjusted OR=1.28[1.01-
1.62], p=0.004). Males displayed a significantly higher prevalence and extent of CAD 
(p<0.001) and more complex coronary lesions (p<0.001) such as left main/three vessel 
disease (p<0.001), complex type C lesions (p<0.001) and the presence of intracoronary 
thrombus (0.05) (Table 2). Moreover males had more often a low TIMI flow grade at 
angiography (p<0.001). All angiographic characteristics according to gender are listed in 
Table 2. 
 
 Uric acid and CAD in women 
Baseline clinical characteristics and angiographic characteristics according to Tertiles of 
serum uric acid in females (Group 1, < 4.8mg/dL or 0.28mmol/mol, n = 349, Group 2, 4.8-
6.3mg/dL – 0.28-0.37mmol/mol, n = 359 and Group 3 > 6.3mg/dL or 0.37mmol/mol, n = 
370) are listed in Table 3. Patients with elevated SUA were older (p<0.001), with higher 
prevalence of hypertension (p=0.02), diabetes (p<0.001) and renal failure (p<0.001), but 
with lower family history of CAD (p=0.001). They had higher levels of white blood cells 
(p=0.01), tryglicerides (p=0.002) and fibrinogen (p<0.001) and higher creatinine (p<0.001), 
glycaemia (p<0.001) and glycosilated haemoglobin (p<0.001) at admission, but lower 
haemoglobin (p=0.05) and HDL-cholesterol (p<0.001). Patients of the Third Tertile were 
more often in therapy with ARBs (p=0.006) and diuretics (p<0.001) at admission, but less 
often with Clopidogrel (p=0.04) and had more frequently dilated cardiomyopathy and 
valvular disease as indication for angiography (p<0.001). Women with higher SUA had a 
higher prevalence of severe CAD (OR [95% CI] = 1.38 [1.16-1.64], p<0.001; age-adjusted 
OR [95% CI] = 1.32 [1.11-1.57], p = 0.002) at coronary angiography with a more frequent 
involvement of left main (p=0.01), left anterior descending (p=0.03) and right coronary 
artery (p=0.006). No other differences were found in other biochemical parameters or 
angiographic characteristics. The significant relationship between uric acid levels and 
prevalence of severe CAD (p<0.001) (Figure 3A) was also confirmed after correction for 
baseline confounding factors (hypertension, age, diabetes, family history of CAD, renal 
failure, indication for angiography, white blood cells, haemoglobin, creatinine, glycaemia, 
glycosylated haemoglobin, tryglicerides, HDL cholesterol, fibrinogen, ARB, diuretics, 
clopidogrel) (adjusted OR [95%CI] = 1.29 [1.03-1.62], p = 0.03), despite no significant 
 relationship was observed with the prevalence of CAD (OR [95% CI] = 1.16 [0.99-1.34], 
p=0.10; age-adjusted OR [95% CI] =1.11 [0.95-1.28[, p = 0.22) (Figure 2A), also after 
correction for all baseline confounding factors (adjusted OR [95%CI] = 0.97 [0.79-1.18], p 
= 0.76). 
 
Table 3. Baseline clinical and angiographic characteristics (per lesion) according to Tertile of SUA 
in Females. 
Baseline Clinical Characteristics 
Females  
 
1° Tertile 
SUA<4.8mg/dL 
(0.28mmol/mol) 
(n = 349) 
2° Tertile 
SUA 4.8-
6.3mg/dL (0.28-
0.37mmol/mol) 
(n = 359) 
3° Tertile 
SUA > 6.3mg/dL 
(0.37mmol-mol) 
(n = 370) 
P value 
Arterial hypertension (%)  72.5 73.2 80.2 0.02 
Age (Mean +-SD) 68.4+10.7 70.3+10.7 73.6+9.7 <0.001 
Smokers (%)     0.57 
Active smokers 19.5 14.2 13.7  
Previous smokers 6.3 9.8 7.9  
Dyslipidemia ( %) 55.5 55.6 54.9 0.88 
Diabetes (%) 29.5 33.1 48.8 <0.001 
Family history of CAD (%) 35 25.4 23.4 0.001 
History of MI (%)  14 17.9 15.3 0.67 
Previous PCI (%)  14.7 16.5 17.2 0.37 
Previous CABG (%) 4.9 6.4 7.9 0.10 
Previous Stroke (%) 3.4 5.6 53 0.74 
Renal failure (%) 18.5 31.7 65.5 <0.001 
Indication for angiography  <0.001 
Stable angina or silent ischemia 
(%) 
22.2 18.5 17.2  
Acute Coronary Syndrome (%) 64.9 66.8 49.9  
DCM or valvular disease (%) 12.9 14.7 33  
Biochemistry     
White Blood Cells (10^5/ml) 7.36+2.42 7.64+2.42 7.92+2.5 0.01 
Platelets Count (10^5/ml) 238.5+62.6 239.7+75.8 233.8+77.5 0.5 
Haemoglobin (g/dl) 12.6+1.46 12.4+1.5 12.3+1.66 0.05 
Creatinine (mg/dl) 0.83+0.32 0.92+0.34 1.2+0.45 <0.001 
Glycaemia (mg/dl) 122+50.9 120.8+45 135.8+64.6 <0.001 
Glycosylated Haemoglobin (%) 6.13+1.25 6.16+1.12 6.6+1.5 <0.001 
Total cholesterol (mg/dL) 173.3+45 168.7+43 168.4+42.2 0.243 
Tryglicerides (mg/dL) 117.2+58.8 125+62 135+79.1 0.002 
HDL cholesterol (mg/dL) 47.1+14.2 45.3+13.9 41.6+12 <0.001 
 LDL cholesterol (mg/dL) 105.8+41.5 100.8+39 107+43.9 0.11 
Reactive protein C (mg/dL) 1.34+3.05 1.56+3.5 1.68+2.7 0.35 
Uric Acid (mg/dl) 3.8+3.9 5.4+5.5 7.7+8 <0.001 
Fibrinogen (mg/dL) 446.8+149.3 457+132.2 488.2+144.6 <0.001 
Therapy at admission     
ACE inhibitors (%) 36.3 33.9 36.3 0.98 
ARB (%) 19.3 25.8 28.2 0.006 
Nitrate (%) 35.3 36.7 34.7 0.85 
Beta blockers (%) 51.4 49.6 51.5 0.98 
Calcium antagonists (%) 19.7 20.7 19.8 0.97 
Diuretics (%) 21.7 32.2 53.9 <0.001 
Statins (%) 43.4 42 40.2 0.39 
ASA (%) 52.2 54.9 51.8 0.9 
Clopidogrel (%) 24.3 22.7 18.2 0.04 
Angiographic characteristics 
 
    
Coronary artery disease (%)§ 61.5 66.3 67.3 0.10 
Left main/trivessel disease (%)§ 17.1 18.1 29 <0.001 
Left main coronary (%)§ 5.5 6.8 10.3 0.01 
Left anterior descending coronary 
(%)§ 
40.2 47.3 48.4 0.03 
Circumflex coronary (%)§ 29.2 30.5 32.2 0.39 
Anterolateral branch (%) § 5 6.1 5.3 0.85 
Right  coronary(%)§ 3 0 0 0.006 
Complex type C lesions (%) 30.7 24.5 25.3 0.08 
Proximal vessel tortuosity (%) 3.9 4.3 2.5 0.22 
Spontaneous dissection (%) 0 1.4 0.6 0.34 
Lesion lenght (mm) 19+11.8 17.9+11.3 18.4+12.1 0.44 
Vessel diameter (mm) 2.86+0.62 2.88+0.56 2.86+0.6 0.86 
Stenosis %(mean SD) 85.5+14.8 84.2+16 84.7+15.1 0.44 
Calcified lesions(%) 21.4 23.8 23.6 0.45 
Bifurcation (%) 19.9 22.9 22.6 0.34 
Chronic total occlusion (%) 11.7 9.1 13.2 0.39 
Intracoronary Thrombus (%) 4.7 4.7 3.1 0.2 
In-stent Restenosis (%) 3.7 2.5 3.7 0.95 
TIMI flow    0.39 
         3 (%) 76 76.2 77.9  
         2 (%) 3.9 5.6 4.2  
         1 (%) 2.2 3.3 2.3  
         0 (%) 17.9 14.9 15.5  
 
 
 Uric acid and CAD in men 
Baseline clinical characteristics and angiographic characteristics according to Tertiles of 
serum uric acid in males (Group 1, < 5.5mg/dL or 0.33mmol/mol, n = 762, Group 2, 5.5-
6.8mg/dL – 0.33-0.40mmol/mol, n = 829 and Group 3 > 6.8mg/dL or 0.40mmol/mol, n = 
851) are listed in Table 4. Patients with elevated SUA were older (p<0.001), with higher 
prevalence of hypertension (p<0.001), renal failure (p<0.001) and previous smoke 
(p=0.009). They had a lower incidence of previous PCI (p=0.008), but they were more often 
in therapy with ACE inhibitors (p=0.001), calcium antagonist (p=0.01) and diuretics 
(p<0.001) at admission. About baseline chemistry patients of the Third Tertile had higher 
level of baseline creatinine (p<0.001), glycaemia (p=0.006), glycosilated haemoglobin 
(p=0.02), total cholesterol (p=0.004), tryglicerides (p<0.001), reactive C protein (p=0.006) 
and fibrinogen (p<0.001) but lower HDL-cholesterol (p<0.001) and haemoglobin (p=0.02). 
Moreover they had more frequently dilated cardiomyopathy and valvular disease as 
indication for angiography (p<0.001). Interestingly elevated Uric acid was associated with a 
trend towards lower prevalence of CAD (OR [95% CI] = 0.91 [0.78-1.01], p = 0.052; age-
adjusted OR [95% CI] = 0.92 [0.79-1.01 = 0.055]) (Figure 2B) that was not confirmed after 
correction for baseline confounding factors (hypertension, age, smoke, previous PCI, renal 
failure, indication for angiography, haemoglobin, basal creatinine, glycaemia, glycosylated 
haemoglobin, total cholesterol, tryglicerides, HDL-cholesterol, reactive protein C, 
fibrinogen, ACE inhibitors, calcium antagonist, diuretics, lesion length, calcified lesions, 
intracoronary thrombus) (Adjusted OR [95%CI] = 0.90 [0.76-1.06], p = 0.22; p gender 
interaction = 0.46). Similarly, no association was found between SUA level and the 
presence of severe CAD (Figure 3B) (OR [95% CI] = 1.01 [0.92-1.12], p = 0.76; age-
 adjusted OR [95% CI] = 1.0 [0.91-1.11] = 0.96), even after correction for baseline 
confounding factors (adjusted OR [95%CI] = 0.89 [0.79-1.01], p = 0.08; p gender 
interaction = 0.002). 
 
Table 4. Baseline clinical and angiographic characteristics (per lesion) according to Tertile of SUA 
in Males. 
Baseline Clinical Characteristics 
Males  
 
1° Tertile 
SUA<5.5mg/dL 
(0.33mmol/mol) 
(n =762) 
2° Tertile 
SUA 5.5-
6.8mg/dL (0.33-
0.40mmol/mol) 
(n =829) 
3° Tertile 
SUA > 6.8mg/dL 
(0.40mmol-mol) 
(n =851) 
P value 
Arterial hypertension (%)  64.2 65.9 78.4 <0.001 
Age (Mean +-SD) 65.4+11.7 65.4+11.4 67.7+11.7 <0.001 
Smokers (%)     0.009 
Active smokers 32.6 34.3 28.3  
Previous smokers 20.1 24.1 27.6  
Dyslipidemia ( %) 53.2 58.3 56.1 0.28 
Diabetes (%) 37.9 34 38.6 0.71 
Family history of CAD (%) 28.3 31.6 26.8 0.48 
History of MI (%)  28.4 27.5 29.5 0.60 
Previous PCI (%)  30.6 27 24.7 0.008 
Previous CABG (%) 13.4 12.8 16.5 0.07 
Previous Stroke (%) 7.6 6.3 9.8 0.10 
Renal failure (%) 12.4 18.3 38.1 <0.001 
Indication for angiography  <0.001 
Stable angina or silent ischemia 
(%) 
27.6 26 23.6  
Acute Coronary Syndrome (%) 60.6 60 52  
DCM or valvular disease (%) 11.8 14 24.4  
Biochemistry     
White Blood cells (10^5/ml) 7.9+3.2 7.9+3.2 8.2+3 0.22 
Platelets Count (10^5/ml) 205.3+59.6 203.8+56.6 211.6+64.2 0.19 
Haemoglobin (g/dl) 13.8+1.6 13.9+1.6 13.7+1.7 0.02 
Creatinine (mg/dl) 0.99+0.32 1.06+0.31 1.22+0.4 <0.001 
Glycaemia (mg/dl) 128.7+53.2 120.8+42.5 129.6+50.3 0.006 
Glycosylated Haemoglobin (%) 6.19+1.3 6.10+1.3 6.3+1.2 0.02 
Total cholesterol (mg/dL) 156.6+38.9 162.2+40.7 162.7+41.3 0.004 
Tryglicerides (mg/dL) 122.6+73.5 137.1+77.7 151.7+98.3 <0.001 
HDL cholesterol 40.9+12.1 39.7+11.5 38+11 <0.001 
LDL cholesterol 98+45.2 101.1+45.7 102+46.8 0.21 
Reactive protein C (mg/dL) 1.2+2.5 1.07+2.5 1.48+2.89 0.006 
Uric Acid (mg/dl) 4.6+0.65 6+0.37 8.1+1.3 <0.001 
 Fibrinogen (mg/dL) 414.4+153 417+146 453.2+155.8 <0.001 
Therapy at admission     
ACE inhibitors (%) 34.5 40 42.5 0.001 
ARB (%) 17.3 17.4 20.7 0.07 
Nitrate (%) 35.2 34.7 37.1 0.4 
Beta blockers (%) 50.7 50.1 52.1 0.56 
Calcium antagonists (%) 18.4 18.6 23.4 0.01 
Diuretics (%) 18.9 22 39.7 <0.001 
Statins (%) 52.2 52.1 48.5 0.13 
ASA (%) 60.6 59.5 59.5 0.66 
Clopidogrel (%) 23.3 24.5 23.4 0.99 
Angiographic characteristics 
 
    
Coronary artery disease (%)§ 83.4 81.9 79.6 0.052 
Left main/trivessel disease (%)§ 32.8 29.8 33.3 0.76 
Left main coronary (%)§ 9.6 9.1 11.5 0.19 
Left anterior descending coronary 
(%)§ 
60.1 53.6 55.5 0.08 
Circumflex coronary (%)§ 46.3 45.1 43.8 0.30 
Anterolateral branch (%) § 10.6 7.6 8.3 0.13 
Right  coronary(%)§ 49.5 49 51.4 0.43 
Complex type C lesions (%) 36.8 34.6 39.4 0.155 
Proximal vessel tortuosity (%) 3.3 4 3.6 0.74 
Spontaneous dissection (%) 0.5 0.4 0.1 0.08 
Lesion length (mm) 21.6+14 19.6+12.3 20+12.8 0.001 
Vessel diameter (mm) 2.94+0.6 2.92+0.62 2.95+0.62 0.36 
Stenosis %(mean SD) 86.4+15.6 87+14 87+14.7 0.52 
Calcified lesions(%) 19.8 22.5 26.9 <0.001 
Bifurcation (%) 22.2 21.9 20.7 0.34 
Chronic total occlusion (%) 19.1 18.2 22 0.053 
Intracoronary Thrombus (%) 6.8 5.3 4.4 0.005 
In-stent Restenosis (%) 5.3 4.7 4.3 0.21 
TIMI flow    0.138 
         3 (%) 69 70.4 66.6  
         2 (%) 4.9 4.7 4.8  
         1 (%) 3.1 2.9 3.5  
         0 (%) 23 21.9 25.1  
 
Figure 1. Bar graph showing the mean values of uric acid in males and females. 
  
Figure 2. Bar graph showing the prevalence of coronary disease according to uric acid tertiles in 
females (Figure 2A) and males (Figure 2B). 
  
Figure 3.  Bar graph showing the prevalence of severe (left main and/or trivessel) coronary disease 
according to uric acid tertiles in females (Figure 3A) and males (Figure 3B). 
 
 Discussion  
The main findings of our study are that: 1) male sex, is independently associated with higher 
SUA; 2) high uric acid levels are independently associated with more severe CAD in 
women. Despite the great improvement in pharmacological and revascularization therapies 
to treat and reduce cardiovascular mortality in the last decades (3-5), especially in the acute 
setting, the results are still suboptimal, in particular among high-risk subgroups of patients 
(6, 7, 18). Therefore, large interest has been focused on the identification of new risk factors 
in order to prevent CAD. Uric acid represents a metabolite of the degradation pathway of 
purines, with renal elimination (19). Its catabolism via the xanthine oxidase has been related 
to increased production of reactive oxygen species and reduced availability of nitric oxide, 
with consequent oxidative damage (20). Therefore, elevated serum uric acid (SUA) has 
been addressed in literature as a potential contributor of cardiovascular risk, but the results 
were conflicting. In the past several studies showed an association between hyperuricemia 
and an increased rate of cardiovascular events and higher mortality (21,22), recently 
confirmed in a large study by Ndrepepa G et al. (23). On the contrary, other large studies, 
such as the Framingham Heart Study, (24) and the study from Panero et al, (25) concluded 
that uric acid was not a causal risk factor for cardiovascular disease. We previously found 
no association between uric acid and the extent of CAD (12). Moreover, it is know that 
serum uric acid levels are lower in women than in men and several studies in the past 
assessed the association between elevated uric acid levels and the extension of CAD, 
cardiovascular events and CAD related mortality in association to sex with important 
contradictions. Fang J et al. showed that increased serum uric acid levels are independently 
and significantly associated with risk of cardiovascular mortality both in women and men 
 (26). A recent study by Onat et al. (27) showed among more than 1500 patients that CAD 
risk was independently predicted by elevated SUA in nondiabetic men and was modulated 
by metabolic syndrome and gender. Subsequently, Tuttle et al. (15) suggested a significant 
association between high uric acid levels and CAD in woman but not in men and these 
results were also confirmed in a more recent meta-analysis by Kim et al. (28) in which 
among 402,997 patients, subgroup analyses showed no significant association between 
hyperuricemia and CAD incidence/mortality in men, but an increased risk for CAD 
mortality in women (RR 1.67, 95% CI 1.30-2.04). Moreover, a recent study by Ndrepepa et 
al. (29) showed between 13,273 patients a stronger association between hyperuricemia and 
an increased risk of mortality in both sex, with a stronger association in women. In line with 
most of the studies, we found that despite the higher uric acid levels observed  in men a 
significant association between uric acid and the severity of CAD was observed only in 
women. In our population women were older, with higher prevalence of the most important 
cardiovascular risk factors and this finding can probably explain the strong association 
between severe CAD and SUA in the female population. Anyway, this association remained 
significant even after correction for all baseline confounders, underlying the presence of an 
independent correlation between elevated SUA and CAD. Therefore, the complex gender-
interaction in the relationship between uric acid and CAD can not only be explained by the 
major cardiovascular risk factors in women, such as diabetes, hypertension and chronic 
renal failure (30). A recent study (31) has shown a significant gender-difference in the 
association between uric acid and MPV, with larger platelets observed in the presence of 
increased uric acid only among women. In fact, MPV has recently been shown to affect 
platelet reactivity (32,33) and may therefore contribute to explain our findings. Future large 
 studies are certainly needed to confirm our findings, to provide physiopathologic insights on 
the observed gender interaction and to evaluate gender-specific benefits from SUA lowering 
therapies on cardiovascular prevention and cardiovascular outcome. In fact, so far weak 
benefits have been demonstrated and therefore their use is, till now, very modest in the 
subset of asymptomatic patients (34-36). 
Limitations 
Our study is not able to provide data about long term effect of SUA on cardiovascular 
outcome. Our study has a cross sectional design, therefore we have no data are regarding the 
follow up of this high risk subgroup of patients. Finally the use of intravascular imaging, as 
with IVUS technique, would have improved the definition of CAD, especially in patients 
with complex eccentric plaques and with negative remodelling, which has been more often 
demonstrated in older patients, as our patients with higher SUA (37).  
Conclusion 
Our study showed that even though uric acid levels are significantly higher in men, high 
uric acid levels are associated with severe CAD only in women. Future large studies are 
certainly needed to confirm our findings and to evaluate the effects of SUA lowering 
therapies on cardiovascular prevention and outcome, especially among women.  
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Abstract 
The neutrophil to lymphocyte ratio (NLR), an inflammatory biomarker, may be of 
predictive and prognostic value for cardiovascular (CV) events. We evaluated the 
relationship of NLR with the prevalence and extent of coronary artery disease (CAD) in 
consecutive patients undergoing elective or urgent coronary angiography. Our population 
(n=3738 patients) was divided into NLR quartiles. Higher NLR was associated with ageing 
and established CV risk factors, previous percutaneous coronary revascularization, acute 
presentation and more complex pharmacological therapy. NLR was related with platelet 
count, WBC count, creatinine, glycemia, uric acid and C reactive protein (all p=0.001) 
levels, but inversely related with hemoglobin (p<0.001), total cholesterol (p=0.005) and 
triglycerides (p<0.001) levels. NLR was associated with multivessel disease (p<0.001), 
anterior descending, right coronary arteries (p<0.001) or circumflex branch lesions 
(p=0.01), percentage stenosis (p<0.001), coronary calcification (p<0.001) and intracoronary 
thrombus (p<0.001) but inversely with instent restenosis (p<0.001) and Thrombolysis-In 
Myocardial-Infarction flow (p=0.04). NLR was directly related with the prevalence of CAD 
(p=0.001) and severe CAD (p<0.001). In patients undergoing coronary angiography, the 
NLR is independently associated with the prevalence and severity of CAD.  
 Keywords: white blood cells, neutrophils, lymphocytes, coronary artery disease; coronary 
angiography 
 
Introduction 
Atherosclerosis is an inflammatory process leading to vascular wall degeneration as a 
response to various risk factors.1 Considerable interest has been given to the field of 
cardiovascular (CV) disease prevention and major advances have been achieved in 
mechanical reperfusion and antithrombotic therapies 2-6, especially in acute myocardial 
infarction. However, the outcome is still unsatisfactory in a relatively large proportion of 
patients 7-9, thus shifting the focus on the identification of new indicators, better allowing to 
stratify the risk of CV events. 10-12 Several inflammatory biomarkers, such as high 
sensitivity C-reactive protein (hsCRP), interleukin-6 and lipoprotein associated 
phospholipase A2, have been associated with coronary artery disease (CAD) 13-15. The WBC 
count has emerged as one of the easiest to obtain, cheapest and moreover, best predictive 
indicators of CV risk 16. In fact, leukocytes play a crucial role in the progression of 
atherosclerosis and in destabilization and rupture of a plaque, leading to thrombotic events. 
17 More recently, attention has shifted to leukocyte subtypes and to the Neutrophil to 
Lymphocyte Ratio (NLR), potentially being more accurate and stable than absolute blood 
cell counts, especially in patients with acute presentation, where it has been associated with 
clinical outcome and procedural results after percutaneous revascularization. 18, 19  However, 
few reports have evaluated the relationship between NLR and the prevalence and extent of 
CAD; this was the aim of the present study.  
 Methods                           
Our population consisted of consecutive patients undergoing elective or urgent coronary 
angiography between April 2007 and December 2013 at the Ospedale “Maggiore della 
Carità”, Novara, Italy. Informed consent was obtained from all patients before angiography. 
The study was approved by our local Ethical Committee. All demographic and clinical data 
were prospectively collected in a dedicated database. Hypertension was defined as systolic 
pressure >140 mmHg and/or diastolic pressure >90 mmHg or if the individual was taking 
antihypertensive medication. Diabetes mellitus was defined as previous diagnosis, specific 
treatment (oral drug or insulin), fasting glycemia >126 mg/dL or glycosylated hemoglobin 
(HbA1c) >6.5%. 20 Chronic renal failure was considered as a history of renal failure or an 
admission glomerular filtrate (GFR) <60 ml/min/1.73m2 as defined by Modifying Diet in 
Renal Disease (MDRD) formula. Non-ST-elevation myocardial infarction was defined as 
chest pain lasting more than 5 min, associated with elevation of cardiac biomarkers beyond 
the upper limit of normal (ULN) (0.04 µg/l for Troponin I and 5.00 ng/ml for creatine-
kinase-MB, respectively), with or without ECG changes.  
Biochemical measurements                                            
Blood samples were drawn at admission in patients undergoing (following a fasting period 
of 12 h) or urgent coronary angiography. Glucose, creatinine, HbA1c and lipid profile were 
determined by standard methods. 
The WBC counts were measured in a blood sample collected in Ethylenediaminetetraacetic 
acid (EDTA) (7.2 mg) tubes. These blood samples were analyzed within 2 h of venipuncture 
using an automatic blood counter (Sysmex XE-2100, Sysmex Corporation, Kobe, Japan). 21 
 Coronary angiography                                                  
Coronary angiography (Siemens AXIOM ARTIS dTC, Erlangen, Germany) was routinely 
performed by the Judkins technique using 6-French right and left heart catheters. 
Quantitative coronary angiography was performed, by an automatic edge-detection systems 
(Siemens Acom Quantcor QCA, Erlangen, Germany) as previously described. 22 The 
measured parameters were minimal luminal diameter, reference diameter, percent diameter 
stenosis and length of the lesion. Significant CAD was defined as at least 1 coronary 
stenosis >50%. Severe CAD was defined as 3-vessel disease and/or left main disease. In 
cases who had previously undergone percutaneous coronary intervention (PCI), even if no 
restenosis was observed, the treated vessel was counted as significantly diseased. In 
previously bypassed patients, native arteries and grafts were taken into account in the 
evaluation of the extent of artery disease (number of diseased vessels). 
 
Statistical analysis                                      
Statistical analysis was performed using SPSS 15.0 statistical package. Continuous data 
were expressed as mean ± SD and categorical data as percentage. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. Patients 
were grouped according to quartiles of NLR. Multiple logistic regression analysis was 
performed to evaluate the relationship between NLR and CAD, even in higher risk subsets 
of patients, after correction for baseline confounding factors that were entered in the model 
in block. A two-sided p value < 0.05 was considered significant.   
 
 
 Table I. Clinical and demographic characteristics according to NLR quartiles.  
Baseline Characteristics  
 
I quart 
(n= 933) 
II quart 
(n=919) 
III quart 
(n=954) 
IV quart 
(n=932) 
P value 
Age (mean +/- SD)  64.3 11.2 66.9 10.9 68.7 10.9 70.4 11.4 <0.001 
Male Sex (%)  67.5 69.9 70.8 69 0.49 
Dyslipidemia (%) 62.1 59.5 54.6 45.4 <0.001 
Diabetes mellitus (%) 37.1 33.5 36.9 39.5 0.13 
Renal failure (%) 9.6 14.6 17.8 24.1 <0.001 
Smokers (%)      <0.001 
 Active smokers  30.9 26.9 25.5 23.2  
Previous smoker  19.2 20.8 17.1 16  
Hypertension (%)  69.4 71.4 72.6 71.5 0.26 
History of MI (%)  25.1 24.9 23.5 24 0.44 
Previous PCI (%)  27.8 26.3 22 18.9 <0.001 
Previous CABG (%) 10.4 13 11 12.4 0.38 
Biochemistry      
Platelet Count (10^3/µl) 212 58 214 57 217 67 224 79 0.001 
Hemoglobin (g/dl) 13.7 1.6 13.6 1.6 13.4 1.8 12.9 1.9 <0.001 
White blood cell count 
(10^3/µl) 
7.1 2.7 7.2 2 7.8 2.2 9.5 3.1 <0.001 
Creatinine (mg/dl) 0.99 0.3 1.04 0.3 1.08 0.4 1.13 0.5 <0.001 
Glycaemia (mg/dl) 121 46 121 45 125 50 137 61 <0.001 
Glycosylated hemoglobin (%) 6.3 1.4 6.2 1.3 6.2 1.2 6.2 1.4 0.73 
Total cholesterol (mg/dL) 167 41 165 42 163 42 160 42 0.005 
Triglycerides (mg/dL) 140 86 140 85 134 82 115 61 <0.001 
HDL cholesterol (mg/dl) 41 12 41 12 41 12 41 13 0.82 
Uric acid (mg/dl) 6.0 1.6 6.1 1.7 6.2 1.8 6.3 2 0.001 
C-reactive protein (mg/dl)  1.1 0.04 2.0 0.07 2.5 0.8 4.1 0.14 <0.001 
Indication to angiography      <0.001 
Stable angina (%) 31.8 27.9 22.4 11.7  
Acute coronary syndrome (%) 53 53.2 58.8 69  
 Arrhythmias/Valvulopathy/LV 
dysfunction (%)  
15.2 18.9 18.8 19.3  
Therapy at admission      
ACE inhibitors (%) 37.7 36.3 38.9 37.7 0.74 
ARB (%) 19 22.4 21.7 17.6 0.43 
Beta-blockers (%) 55.6 53.9 50.3 42.1 <0.001 
Calcium antagonists (%) 19.2 21.1 21.7 17.2 0.53 
Nitrates (%) 34.6 36.2 36.7 33.4 0.67 
Diuretics (%) 25.5 28.2 33.4 32.4 <0.001 
Statins (%) 53.2 50.5 48.7 38.7 <0.001 
ASA (%) 62.7 62.1 56.9 47.8 <0.001 
 Clopidogrel (%) 23.4 23.4 24.8 19.2 0.08 
 
Results 
Our population consisted of 3738 patients undergoing coronary angiography. They were 
divided according to quartiles values of NLR (< 1.8; 1.8-2.49; 2.5-3.69; >3.7). The main 
clinical and demographical features of included patients are displayed in Table 1. Higher 
NLR values were associated to ageing (p<0.001), dyslipidemia (p<0.001), renal failure 
(p<0.001), smoking (p<0.001), previous PCI (p<0.001), acute presentation (p<0.001), 
therapy at admission with beta-blockers, diuretics, statins and acetylsalicylic acid (p<0.001, 
respectively). NLR was directly related with the platelet count (p=0.001), WBC count, 
creatinine, glycemia (p<0.001), uric acid (p=0.001) and C-reactive protein (p<0.001) levels, 
while inversely with hemoglobin levels (p<0.001), total cholesterol (p=0.005) and 
triglycerides (p<0.001) levels. Table 2 shows main angiographic features according to NLR 
quartiles.  
Table 2. Angiographic characteristics (per lesion) according to Neutrophil to Lymphocyte Ratio. 
Variable  I quart 
(n= 1368) 
II quart 
(n=1468) 
III quart 
(n=1444) 
IV quart 
(n=1626) 
 
P value 
Multivessel (%)§ 40.9 45.6 45.9 51.4 <0.001 
Left main coronary artery (%)§ 9 8.3 9.8 9.9 0.33 
Left anterior descending coronary 
artery (%)§ 
48 53.4 52.8 57.9 <0.001 
Circumflex coronary artery (%)§ 36.7 40.1 39.4 44.9 0.01 
Right coronary artery (%)§ 40 44.8 43.9 50.7 <0.001 
Type C lesions (%) 34.4 34.1 33.7 36.6 0.25 
Lesion length, mm (mean SD) 19.8 13 19.9 12.8 19.9 12.7 19.9 12.8 0.99 
Vessel diameter, mm (mean 
SD) 
2.9 1 3 1.3 2.9 0.7 3 1 0.94 
Stenosis % (mean SD) 85.2 15.7 85.7 15.7 85.7 14.3 87.9 13.9 <0.001 
Calcified lesions (%) 18.1 22.2 24.9 28.1 <0.001 
Bifurcation (%) 21.8 21.2 23.6 20.7 0.77 
 Intracoronary Thrombus (%) 3.7 2.9 5.6 9.1 <0.001 
Chronic occlusion (%) 18.3 18.8 17.1 16.7 0.07 
In-stent Restenosis (%) 6.3 5.4 3.7 2.5 <0.001 
TIMI flow     0.04 
         3 71.9 70.6 72.4 67.6  
         2 4.7 4.6 5.1 5.1  
         1 2.7 3 3.1 3.5  
         0 20.7 21.8 19.3 23.8  
 
 
Higher NLR was associated with the extent of multivessel coronary disease (p<0.001) and 
with lesion location (p<0.001). NLR was related with the percentage of stenosis (p<0.001), 
the presence of coronary calcification (p<0.001), intracoronary thrombus (p<0.001) and 
inversely with instent restenosis (p<0.001) and TIMI flow (p=0.04).  
 
Figure 1. Bar graphs showing the relationship between Neutrophil to lymphocyte ratio (NLR) 
quartiles values and the prevalence of coronary artery disease (CAD).  
 
 
 As shown in Figure 1, NLR was directly related with the prevalence of CAD (73.1 vs 76.4 
vs 75.6 vs 80.4, p=0.001; OR [95%CI] = 1.12 [1.05-1.2], p=0.001) and with the prevalence 
of severe CAD (24.3 vs 27.3 vs 28.5 vs 33.6%, p<0.001; OR [95%CI] = 1.16 [1.08-1.23], 
p<0.001) (Figure 2).  
 
 
Figure 2. Bar graph showing the relationship between Neutrophil to lymphocyte ratio (NLR) 
quartiles values and the prevalence of severe coronary artery disease (CAD)  
 
 
 
Results were confirmed after correction for baseline differences for both prevalence of CAD 
(adjusted OR [95%CI] = 1.11 [1.01-1.22], p=0.04) and severe CAD (adjusted OR [95%CI] 
= 1.12 [1.03-1.23], p=0.007). Similar results were confirmed in the majority of high risk 
subsets of patients when considering high (4th quartile) vs all lower NLR quartiles. Data for 
each subgroup are shown in Figure 3, including elderly (≥75 years, OR = 1.55 [1.14-2.11], 
 p=0.006) or young patients (<75 years old, OR=1.23 [0.97-1.54], p=0.08, p 
interaction=0.23), males (OR=1.26 [1-1.60], p=0.05) and females (OR=1.59 [1.19-2.14], 
p=0.002, p interaction=0.21), according to diabetes (diabetics: OR=1.59 [1.13-2.25], p=0.01 
and non-diabetics: OR=1.25 [1.001-1.56], p=0.05, p interaction=0.24), renal function (renal 
failure: OR=1.37 [1-1.88], p=0.05; normal function: OR=1.38 [1.09-1.74], p=0.007, p 
interaction=0.97), hypertension  (hypertension: OR=1.34 [1.07-1.67], p=0.01, no 
hypertension: OR= 1.39 [1.002-1.92], p=0.048, p interaction =0.85).  
 
Figure 3 Forest plot showing the risk of coronary artery disease (CAD) for Neutrophil to 
lymphocyte ratio (NLR) in IVth quartile vs lower values in higher risk subsets of patients (CKD = 
chronic kidney disease).  
 
 
 Discussion 
This is the largest single-center cohort study conducted so far that evaluated the relationship 
between the NLR and angiographically defined CAD. Our main finding is that higher NLR 
values are associated with the extent and severity of coronary lesions, independently from 
the main established CV risk factors and in the majority of higher risk subsets of patients. 
Pharmacological and technical innovations have changed the approach to patients with 
CAD, extending the indication for PCI to more complex subsets of patients, especially those 
with acute coronary syndromes (ACS), reducing the rate of repeated target vessel 
revascularization and increasing event-free survival. 23-29 Indeed, potent antiplatelet agents, 
new anti-ischemic drugs and high-dose statins have contributed to reduce the progression of 
atherosclerosis and CV disease, although a considerable residual risk of acute events 
remains. 30-32 Therefore, there is a need to identify new markers to allow better risk 
stratification and also as potential pharmacological targets. Special attention has been 
dedicated to inflammatory biomarkers, with contrasting results. 33 Indeed, inflammation 
plays a central role in the pathogenesis of atherosclerosis and an elevation of inflammatory 
markers, indicates the activation of vascular damage. 34 However, a modest potential of 
predicting CV events has been reported in patients without established CAD, even with 
complex combinations of indicators of acute response and endothelial dysfunction. 17, 35 
Moreover, initial attempts to target selective inhibition of cytokines in CV prevention has 
resulted in inconsistent results. 36,37 The WBC count represents a cheap, widely available 
and early indicator of the inflammatory response and initial studies showed that an elevation 
of total WBC was associated with increased mortality and worse outcomes after acute 
 myocardial infarction (MI). 38,39 Thereafter, with the recognition of a more relevant role for 
immune rather than inflammatory response, in the pathogenesis of CAD, attention has been 
addressed to leukocyte subtypes and especially the NLR, combining the effects of the non-
specific inflammatory response, mediated by neutrophils, and the subsequent regulatory 
immune response, involving lymphocytes. 40 Neutrophils have been claimed for every step 
leading to acute coronary events and can release pro-oxidant and pro-thrombotic substances, 
leading to endothelial damage and platelet aggregation. A low lymphocyte count has also 
been associated with worse prognosis in patients with CAD and unstable angina 41, as 
certain subset of lymphocytes, have been shown to play an inhibitory role in atherosclerosis, 
possibly by controlling and regulating the inflammatory response. 40 An increased NLR has 
been related with arterial stiffness and with indirect indicators of atherosclerosis, such as 
coronary calcium score and carotid intima-media thickness. Moreover, this hematological 
index has been associated with thrombus formation in ACS 42, where it has been suggested 
to influence short and long- outcome, especially in patients with ST elevation MI (STEMI) 
undergoing primary PCI. 43, 44 In particular, in a large cohort of STEMI patients, a NLR 
>6.97 was associated with increased in-hospital and long-term CV mortality 45, and similar 
results were identified in a Korean population. 46 Recent studies, in addition, have reported a 
prognostic role of NLR in patients undergoing elective PCI or surgical coronary 
revascularization 22,47 and NLR was associated with worse outcome at 3 years follow-up 
independently from the therapeutic strategy selected for CAD. 48 In addition, the authors 48 
suggested a more advanced obstructive CAD (OR = 2.45, CI 95% 1.76, 3.42, p < 0.001) in 
patients with higher NLR. However, only few small studies have evaluated the relationship 
between NLR and angiographic findings, thus not providing conclusive results. We present 
 the results from the largest single center cohort of patients undergoing coronary 
angiography. We identified a relationship between NLR and main established CV risk 
factors, thus confirming the hypothesis that the vascular damage induced by ageing, 
hypercholesterolemia, smoking, hyperglycemia could be mediated by the immune response. 
Moreover, NLR showed a direct association with acute presentation and with inflammatory 
biomarkers, as C-reactive protein. In our patients, the NLR was independently associated 
with the prevalence and extent of CAD (with results being confirmed after correction for 
potential confounders) and with higher complexity of the coronary plaque, including 
calcified lesions, intracoronary thrombus and stenosis. Results, in addition, were confirmed 
also in the majority of high-risk subsets of patients. Our findings confirm the results 
reported by Kaya et al, in 186 patients undergoing coronary angiography, where NLR was 
related with the complexity of CAD assessed by SYNTAX score. 49 Similar conclusion was 
reached by Altun et al 50, in a Scandinavian cohort of 287 ACS patients and by Açar et al 51 
in 283 patients evaluated by Coronary Computed Tomography, where NLR values in the 
third tertile increased the risk of CAD and the severity of critical luminal stenosis. 
Therefore, the present study provides a deeper insight in the stratification tools for assessing 
the risk of CAD and in the role of immune response in the pathogenesis of CAD, suggesting 
the hypothesis of immune-modulation as a potential pharmacological target for the 
prevention of CV disease. In fact, Wang et al. demonstrated a positive effect of diet and 
exercise on NLR. 52 Limitations of the study are mainly those inherent to any prospective 
but observational study. In fact, we did not collect follow-up data, especially in patients 
undergoing coronary angioplasty, and thus cannot provide data on the role of NLR on the 
progression of CAD, and especially on the risk of adverse events, as stent thrombosis or 
 restenosis after PCI. It is known that inflammation plays a key role in in-stent restenosis 
process.53 However, we have found an inverse paradoxical association between NLR and in-
stent restenosis. However, our data should be interpreted with caution. In fact, evaluation of 
in-stent restenosis was not the aim of our study, and we took note of significant in-stent 
restenosis but not of segments with successful stent results, with a subsequent evident bias. 
In addition, patients with higher NLR were more often on statins and that could potentially 
explain the lower rate of restenosis and lower levels of cholesterol in patients with high 
NLR. This does not certainly allow to generate any hypothesis from present findings. 
However, more dedicated studies would certainly be helpful in clarifying these issues. In 
addition, the use of intracoronary ultrasound or virtual histology would have improved our 
results by providing more accurate information on the coronary atherosclerotic plaque, as in 
fact previous reports have related NLR to coronary ectasia 54 The present study 
demonstrates that in patients undergoing coronary angiography, higher NLR values emerge 
as independent predictors of the prevalence and extent of CAD.  
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Abstract 
Background. Contrast Induced Nephropathy (CIN) is a complication of coronary 
angiography/percutaneous intervention (PCI). It is known that diabetes is an independent 
risk factor for CIN, but we have no data regarding the association between CIN and 
glycemic levels in patients without diabetes. Aim of our study was to evaluate whether high 
level of glycated-haemoglobin in patients without diabetes is associated with an increased 
risk of CIN. 
Methods. 1831 patients without diabetes, undergoing elective/urgent coronary 
angiography/angioplasty were divided according to quartiles of baseline glycated-
haemoglobin. CIN was defined as an absolute ≥0.5mg/dl or a relative ≥25% increase in 
creatinine level at 24-48h after the procedure. 
Results. Patients with elevated glycated-haemoglobin were older, with hypertension, 
previous history of AMI, PCI and CABG. They had higher gycaemia, fasting-glycaemia and 
 triglycerides but lower HDL-cholesterol. Patients with higher glycated-haemoglobin were 
more often on therapy with statins, diuretics and calcium-antagonist at admission, had 
higher basal, 24 and 48h creatinine and lower creatinine clearance. They had the highest 
incidence of PCI and contrast volume-eGFR rate. CIN occurred in 10.6% of patients with a 
linear association with glycated-haemoglobin (p=0.001). No relationship was found 
between glycaemia/fasting glycaemia at admission and CIN. At multivariate analysis 
age>70years (AdjustedOR[95%CI]=1.70[1.18-2.42],p=0.004) and glycated-haemoglobin 
(AdjustedOR[95%CI]=1.63[1.12-2.36],p=0.01) were independently associated with the risk 
of CIN. The subgroups analysis showed similar results. 
Conclusion. This is the first study showing that among patients without diabetes 
undergoing coronary angiography/PCI elevated glycated-haemoglobin but not glucose 
levels is independently associated with the risk of CIN. 
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 Introduction 
Contrast Induced Nephropathy (CIN) is one of the major complications of procedures that 
foresee the use of contrast media and is associated with a poor long-term clinical outcome 
(1,2). It is commonly defined as an acute deterioration in renal function characterized by a 
significant increase in serum creatinine levels, usually more than 0.5mg/dl or 25% of 
baseline levels, within 24-48h after exposure to a contrast agent compared to baseline serum 
creatinine values. In particular in patients undergoing diagnostic and/or therapeutic coronary 
angiography it has shown to occur in up to 20-25% depending on the presence of known 
risk factors, such as chronic kidney disease, diabetes mellitus, the dose of contrast medium 
(3,4). Due to the improvement in stent technology and antithrombotic therapies (5-10), a 
yearly growing number of patients is now revascularized percutaneously, with a larger 
proportion of high-risk patients, including those with impaired renal function. In patients 
with chronic kidney disease, with an estimated glomerular filtration rate (eGFR) 
<60ml/min, there is a loss of nephron units with a poor residual renal function more 
vulnerable to renal insults. The pathogenesis of contrast induced acute kidney injury is the 
result of endothelial dysfunction, cellular toxicity from the contrast agent and tubular 
apoptosis resulting from hypoxic damage or reactive oxygen species (11). The use of 
contrast media superimposed acute vasoconstriction, caused by the release of adenosine and 
endothelin, with the reduction in renal blood flow to the outer medulla, consequent 
medullary hypoxia, ischemic injury and death of renal tubular cells (12). Hyperglycemia 
leads to increased endothelin and angiotensin levels, causing intrarenal vasoconstriction; it 
also modifies the regulation of intrarenal blood flow increasing the medullary lactate level, 
reducing pH and oxygen delivery and increasing reactive oxygen species and oxidative 
 stress (13-14). It is known that diabetes mellitus is an independent risk factor for contrast 
induced nephropathy (15-16), because of altered renal oxygen supply and enhanced reactive 
oxygen species generation, but we have no data regarding the association between glycemic 
levels in patients without diabetes and the risk of contrast induced nephropathy (17). 
Therefore, the aim of the current study was to evaluate whether high level of glycated 
haemoglobin in patients without diabetes undergoing elective coronary angiography, 
percutaneous intervention or urgent coronary angioplasty, is associated with an increased 
risk of contrast induced acute kidney injury. 
Material and Methods 
Our population is represented by 1831 consecutive patients undergoing coronary 
angiography and/or angioplasty at Catheterization Laboratory of AOU “Maggiore della 
Carità”, Novara, from January 2007 to September 2011, who were included in our registry 
on coronary artery disease, as previously described (18), and did not meet the diagnostic 
criteria for diabetes mellitus, defined as previous diagnosis, specific treatment 
administration (oral or insulin), fasting glycemia > 126 mg/dL or HbA1c > 6.5% - 
47mmol/mol (19). Informed consent was obtained by all patients before angiography. The 
study was approved by our local ethical committee. All demographic and clinical data were 
prospectively collected in a dedicated database. Hypertension was defined as systolic 
pressure > 140 mm Hg and/or diastolic pressure was > 90 mm Hg or if the individual was 
taking antihypertensive medications. Metabolic syndrome was defined according to the 
guidelines of the International Diabetes Federation by the presence of three or more of these 
characteristics: obesity on the basis of waist circumference (males >94 cm, females >80 
 cm), tryglycerides >150mg/dL, low HDL-cholesterol (M: <40 mg/dL; F: <50 mg/dL), 
hypertension (>130/>85 mmHg) and fasting glycaemia >110mg/dL (20). All patients were 
hydrated with saline solution 1ml/kg/h 12h before and after the procedure or with saline 
solution 0,5ml/kg/h (ejection fraction ≤ 40%) or with sodium bicarbonate (154 mEq/l in 
dextrose and water received 3 ml/kg for 1h before contrast exposure followed by an infusion 
of 1 ml/kg/h for 6h after the procedure) for primary PCI. Acute kidney injury was defined as 
an absolute ≥ 0.5mg/dl or a relative ≥ 25% increase in the serum creatinine level at 24 or 
48h after the procedure. 
Coronary angiography was routinely performed by the Judkins technique using 6-French 
right and left heart catheters through the femoral or radial approach. Quantitative coronary 
angiography (Siemens Acom Quantcor QCA, Erlangen, Germany) was performed by two 
experienced cardiologists who had no knowledge of the patients' clinical information (21). 
Significant coronary artery disease was defined as at least 1 coronary stenosis more than 
50%. Severe multivessel disease was defined as three-vessel disease and/or left main 
disease. Coronary angioplasty was performed with standard techniques (22). Use of stents, 
type of stents and stent implantation techniques, as much as the use of directional or 
rotational  atherectomy, IVUS, glycoprotein IIb-IIIa inhibitors, was left at the discretion of 
the operators. The contrast medium used was non-ionic, iso-osmolar (Optiray, Visipaque, 
Ultravist). All patients received, according to guidelines, high-dose bolus of clopidogrel 
(600 mg) at the time of hospitalization or before angioplasty.  
Biochemical measurements 
Blood samples were drawn at admission in patients undergoing elective (following a fasting 
period of 12 h) or urgent coronary angiography. Glucose, glycated haemoglobin, creatinine 
 and haemochrome were determined by standard methods. Creatinine was measured at 12, 
24 and 48 hours after the procedure or longer in case of development of contrast induced 
nephropathy.  
Statistical analysis 
Statistical analysis was performed with the SPSS 15.0 statistical package. Continuous data 
were expressed as mean + SD and categorical data as percentage. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. A trend 
analysis was performed as previously described (23). Multiple logistic regression analysis 
was performed to evaluate the relationship between glycated haemoglobin levels and CIN, 
after correction for baseline confounding factors (clinical and demographic variables with a 
p value < 0.2 at univariate analysis), that were entered in the model in block.  
 
Table 1. Baseline Clinical Characteristics according to quartiles of glycated haemoglobin. 
Variable I Quartile 
HbA1c < 
5.4% (36 
mmol/mol) 
(n = 326) 
II Quartile 
HbA1c 5.4-
5.7% (36-39 
mmol/mol) 
(n = 270) 
III Quartile 
HbA1c 5.7-
6% (39-42 
mmol/mol) 
(n = 379) 
IV Quartile 
HbA1c > 6% 
(42 
mmol/mol) 
(n = 349) 
p-value 
Demographic  and 
clinical characteristics 
     
Age (M-SD) 64.2+13.04 67.2+10.9 68.22+10.74 70+10.42 <0.001 
Sex (M %) 70.9 68.1 69.4 70.2 0.935 
Hypertension (%) 60.2 67.8 72.9 68.3 0.01 
Smokers (%)     0.229 
Active smokers (%) 27.7 21.6 23.9 25  
Previous smokers (%) 16 22 19.5 13.6  
Hypercolesterolemia (%) 47.7 60.4 55.4 55 0.142 
Family history of CAD 
(%) 
31.5 35.9 30 28 0.22 
Previous AMI (%) 17.6 21.9 26.4 28.9 <0.001 
Previous PCI (%) 14.5 21.5 20.3 21.6 0.035 
Previous CABG (%) 7.7 12.2 8.7 13.8 0.045 
Previous Stroke (%) 7.1 5.6 6.3 5.2 0.39 
Indication for     0.28 
 angiography 
Stable angina or silent 
ischemia (%) 
18.7 24.1 22.2 21.7  
Acute Coronary 
Syndrome (%) 
58 57.8 49.6 49.7  
DCM or valvular disease 
(%) 
23.3 18.1 28.2 28.6  
Baseline Chemistry      
White blood cells 
(10^3/µl) (M-SD) 
7.49+2.87 7.28+2.32 7.75+2.18 7.96+3.61 0.007 
Red blood cells 
(10^6/µl) (M-SD) 
4.55+0.6 4.61+0.52 4.57+0.66 4.55+0.53 0.85 
Haemoglobin (M-SD) 
(g/dl) 
13.5+1.79 13.66+1.57 13.49+1.61 13.43+1.6 0.35 
Platelet (M-SD) 
(10^5/ml) 
214+65.5 209.2+59.4 215+64.8 217.9+62.9 0.25 
Fibrinogen (M-SD) 
(mg/dL) 
445.7+153.8 434+120.5 449.7+145.8 459.6+151.9 0.11 
Glycaemia at admission 
(M-SD) (mg/dL) 
105+17.3 106.9+19.9 109.8+19.2 112.1+21.4 <0.001 
Glycated Haemoglobin 
(M-SD) (%) 
5.17+0.27 5.56+0.05 5.78+0.08 6.14+0.13 <0.001 
Fasting Glycaemia (M-
SD) (mg/dL) 
101.8+13.8 102.9+15.5 106.5+15.2 108.9+18.6 <0.001 
Basal Creatinine (M-SD) 
(mg/dL) 
1 + 0.27 1.03 + 0.29  1.09 + 0.37 1.13 + 0.4 <0.001 
24h Creatinine (M-SD 
(mg/dL) 
1.02 + 0.32 1.02 + 0.3 1.08 + 0.38 1.14 + 0.4 <0.001 
48h creatinine (M-SD) 
(mg/dL) 
0.82 + 0.57 0.91 + 0.55 0.96 + 0.6 1.04 + 0.65 <0.001 
Baseline Creatinine 
Clearance (M-SD) 
(ml/min) 
80.2+32.8 75.5+29.2 74.3+31.2 68.3+30.8 <0.001 
Creatinine Clearance 
<60 (%) 
32.8 37.8 37.5 48.9 < 0.001 
Total Cholesterol (M-
SD) (mg/dL) 
160.7+38.2 165.7+41.4 162.5+37.2 162.3+39.4 0.86 
HDL-Cholesterol (M-
SD) (mg/dL) 
41.3+13.2 41.7+11.2 40.1+11 39.9+12.7 0.04 
Triglycerides (M-SD) 
(mg/dL) 
130.1+76.5 131.8+73 140.3+72.2 144.1+69.2 0.005 
LDL-Cholesterol (M-
SD) (mg/dL) 
94.1+33.2 98+35.7 94.9+32 95.4+35.4 0.92 
Theraphy at admission      
ACE I (%) 34.4 38.5 36.9 38.9 0.30 
ARB (%) 15 21.1 17.2 19.4 0.30 
Statins (%) 40.2 46.7 49.9 47.4 0.03 
Nitrate (%) 28.5 38.5 39.8 33.7 0.13 
 Beta-Blockers (%) 46 52.2 47.8 53.4 0.13 
ASA (%) 50.9 64.1 58.8 59.7 0.06 
Clopidogrel (%) 30 35.7 29.1 25.6 0.11 
Calcium Antagonist (%) 16.6 17.8 20.6 22 0.04 
Diuretics (%) 19.3 21.5 27.7 32.9 <0.001 
Procedural 
characteristics 
     
PCI (%) 41.2 45.7 50.5 50.9 0.006 
Contrast Volume (M-
SD) 
212.4+147.9 225.1+148.5 229.4+156.2 229.8+139.8 0.12 
Contrast volume/eGFR 3.25+3.34 3.44+2.97 3.66+2.98 4.09+3.32 <0.001 
Hydration Protocol     0.158 
SS 1 ml/kg/h (%) 78.2 78.1 76.8 70.3  
SS 0.5 ml/kg/h (%) 8.9 7.8 10.3 13.4  
Sodium Bicarbonate (%) 12.9 14.1 12.9 16.3  
M = Mean; SD = Standard Deviation; CAD: coronary artery disease; AMI: acute myocardial infarction; PCI: 
percutaneous coronary intervention; CABG: coronary artery by-pass graft surgery; DCM: dilated 
cardiomyopathy; HDL: high-density lipoprotein; LDL: low density lipoprotein; ACE I: angiotensin converting 
enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; SS: saline solution. 
 
 
Results 
Our population is represented by consecutive 1831 patients without diabetes. A total of 507 
patients were excluded because of end stage renal failure requiring dialysis or because basal 
glycated haemoglobin levels were not available. Therefore our final study population was 
represented by 1324 patients. Patients were divided according to quartiles of baseline 
glycated haemoglobin (Group 1, < 5.4% - 36mmol/mol, n = 326; Group 2, 5.4-5.7% - 36-
39mmol/mol, n = 270; Group 3, 5.7-6% 39-42mmol/mol, n = 379; Group 4, > 6 – 
42mmol/mol, n = 349). The baseline patients’ clinical and demographic characteristics, 
indication for angiography, procedural main characteristics, baseline chemistry and 
admission therapy, according to the quartiles of glycated haemoglobin levels, are listed in 
Table 1. Patients with elevated glycated-haemoglobin levels were older (p<0.001), with 
history of hypertension (p=0.01) and previous acute myocardial infarction (p<0.001), 
 previous percutaneous coronary intervention (p=0.035) and previous coronary artery by-
pass graft (CABG) (p=0.045). They had higher levels of white blood cells (p=0.007), higher 
glycaemia (p<0.001), glycated haemoglobin (p<0.001) and fasting glycaemia (p<0.001), 
higher tryglicerides (p=0.005) and lower HDL-cholesterol (p=0.04). In addition, patients 
with higher levels of glycated haemoglobin were more often on therapy with statins 
(p=0.03), diuretics (p<0.001) and calcium antagonist (p=0.04) at admission. Patients with 
elevated glycated haemoglobin had higher basal creatinine (p<0.001), lower creatinine 
clearance (p<0.001) and higher creatinine values also at 24 hours (p<0.001) and 48 hours 
(p<0.001) after coronary angiography or percutaneous intervention. About procedural 
characteristics patients of the fourth quartiles had the highest incidence of percutaneous 
intervention (p=0.006) and the highest contrast volume-eGFR rate (p<0.001). No other 
differences were found in biochemical parameters, clinical characteristics, therapy or 
procedural characteristics. Contrast induced nephropathy occurred in 141 patients (10.6%) 
with a significant linear association with glycated haemoglobin (6.7% in Group 1 versus 
9.3% in Group 2, 11.1% in Group 3 and 14.9% in Group 4) (p=0.001) (Figure 1A), whereas 
no relationship was found between glycaemia at admission (p = 0.55) (Figure 1B) or fasting 
glycaemia (p=0.96) (Figure 1C) and the risk of CIN.  
 
 
 
 
 
 Figure 1. Bar graph showing the relationship between the development of contrast induced 
nephropathy and: glycated haemoglobin levels (A), glycaemia at admission (B) and fasting 
glycaemia (C). 
 
 
We identify other 3 variables associated with the risk of CIN: Age > 70 years (OR [95% CI] 
= 1.78 [1.25-2.53], p = 0.001), Female gender (OR 1,38 [95%CI] = [1,01-1,91], p = 0.047), 
use of diuretics (OR [95% CI] = 1.51 [1.04-2.20], p = 0.03). However, at multivariate 
analysis only age > 70 years (Adjusted OR [95% CI] = 1.70 [1.18-2.42], p = 0.004) and 
glycated haemoglobin (Above the 2 quartile) (Adjusted OR [95% CI] = 1.63 [1.12-2.36], p 
= 0.01) were independently associated with the risk of CIN. At subgroup analysis we 
showed the association between the risk of contrast induced nephropathy and major risk 
factors among our population (Above the 2 quartile).  
 Figure 2. Relationship between glycated haemoglobin levels and the risk of contrast induced 
nephropathy (CIN) in major subgroups of patients according to age, gender, hypertension, 
metabolic syndrome and baseline renal failure. 
 
 
 
Data for each subgroup are shown in Figure 2, according to gender (Female gender: 
adjusted OR= 1.56 [0.86-2.84], p=0.14; Male gender: adjusted OR= 1.85 [1.16-2.95], 
p=0.009, P int 0.66), age  (age < 70: adjusted OR = 1.45 [0.87-2.58], p=0.14; age> 70: 
adjusted OR= 1.74 [1.04-2.90], p=0.03, P int 0.69), creatinine clearance (creatinine 
clearance >60: adjusted OR = 1.59 [0.97-2.56], p=0.06; creatinine clearance < 60: adjusted 
OR= 1.89 [1.05-3.40], p=0.03, P int 0.66), history of hypertension (no-hypertension: 
adjusted OR = 1.83 [0.95-3.56], p=0.07; hypertension: adjusted OR= 1.77 [1.13-2.75], 
p=0.01, P int 0.93) and the presence of metabolic syndrome (no metabolic syndrome: 
 adjusted OR = 1.71 [1.05-2.79], p=0.03; metabolic syndrome: adjusted OR= 1.87 [1.05-
3.33], p=0.03, P int 0.82). 
Discussion 
Our study shows that in patients without diabetes undergoing coronary angiography or 
percutaneous interventions, glycated haemoglobin, but not fasting glycaemia, is 
independently associated with an increased risk of contrast induced nephropathy. Coronary 
artery disease is still the first cause of mortality in developed countries. However, a larger 
application of revascularization procedures, especially in the setting of acute myocardial 
infarction (24-27), has contributed to the relevant reduction in mortality observed in the last 
decades. Due to the improvement in stent technology and antithrombotic therapies (5-10), a 
yearly growing number of patients undergo percutaneous revascularization, with a larger 
proportion of high-risk patients, including those with impaired renal function. 
In this kind of patients there is a loss of nephron units with a residual renal function more 
vulnerable to external insults. The development of contrast induced acute kidney injury is 
associates with increased mortality and morbidity costs, in fact, although usually transient, 
the impairment of renal function may be permanent in some cases with progression to 
chronic renal failure and the necessity of a temporary or permanent dialysis (28). Proposed 
pathophysiologic mechanism through which contrast administration may potentiates renal 
injury include oxidative stress, free radical damage and endothelial dysfunction (29). The 
use of contrast media superimposed acute vasoconstriction, caused by the release of 
adenosine and endothelin, with the reduction in renal blood flow to the outer medulla, 
consequent medullary hypoxia, ischemic injury and death of renal tubular cells (12). 
 Prevention is the key to reduce the incidence of contrast induced nephropathy and it begins 
with the identification of the high risk patient coupled with appropriate periprocedural 
management (hydration and administration with acetylcysteine) (30-31). From the current 
literature we know that diabetes is an independent risk factor for contrast induced 
nephropathy (15-16) because of intensified hypoxic and oxidative stress following the 
administration of contrast media. In a “diabetic kidney” there is an enhanced tubular 
transport activity, oxygen consumption, and generation of reactive oxygen species; 
moreover there is a reduction of renal blood flow caused by an altered regulation of vascular 
tone particularly due to defective nitrovasodilation, enhanced endothelin production, and a 
particular hyperresponsiveness to adenosine-related vasoconstriction. In addition, micro- 
and macrovascular diseases and chronic tubulo-interstitial changes further compromise 
regional oxygen delivery, and renal antioxidant capacity might be hampered (17).  
A condition of hyperglycemia, also in a patient without diabetes, leads to increased 
endothelin and angiotensin levels, causing intrarenal vasoconstriction and modifies the 
regulation of intrarenal blood flow increasing the medullary lactate level, reducing pH and 
oxygen delivery and increasing reactive oxygen species and oxidative stress (13-14). In the 
literature there are a lot of studies regarding acute-stress hyperglycemia and the increased 
risk of contrast induced nephropathy in ST-segment elevation myocardial infarction 
(STEMI) patients. Marenzi et al (32) showed that in a group of 780 STEMI patients 
undergoing primary percutaneous coronary intervention acute hyperglycaemia is an 
independent predictor of contrast induce nephropathy and increases in-hospital mortality 
(38%). Similar impact of hyperglycaemia on the risk of contrast induced nephropathy was 
observed in the study by Stolker et al (33) and by Naruse et al (34) among patients 
 undergoing emergency coronary angiography. However, no study has so far investigated the 
relationship between glycated haemoglobin (that is a more stable parameter and therefore 
better representative of chronic glycemic control) and contrast induced nephropathy in 
patients without diabetes. In our population of patients we demonstrated a significant 
relationship between glycated haemoglobin levels and the contrast induced nephropathy 
percentage that was confirmed at multivariate analysis after correction for baseline 
confounding factors. Interestingly, patients of the third and fourth quartiles had glycated 
haemoglobin levels suggesting for a pre-diabetic condition. As diabetes is one of the most 
important risk factor for the development of contrast induced nephropathy, this observation 
reinforced our findings and supports the importance of a correct management of this high 
risk subgroup of patients. On the other side, no relationship was found between fasting 
glycaemia and the occurrence of contrast induced nephropathy. Several factors may explain 
the absence of any relationship between glycaemia and contrast induced nephropathy. First 
of all only a minority of patients underwent primary angioplasty (therefore angiography and 
angioplasty soon after admission). In addition, while acutely elevated glycaemia may also 
be a surrogate marker of impaired haemodynamic instability, glycated haemoglobin 
represents a better reliable marker of chronic glycaemic control. Furthermore, we excluded 
patients with diabetes and therefore those patients expected to have higher fasting glucose 
levels or glucose at admission. In fact, it is well known that diabetes is associated with 
increased risk of contrast induced nephropathy. Finally, HbA1c could be considered a good 
marker for glycated proteins, which plays a contributory role in atherosclerosis (35, 36) not 
only in patients with diabetes, but also in subjects without diabetes (37). This is supported 
 by the findings that even subjects that don’t meet diagnostic criteria for diabetes with 
coronary artery disease have increased levels of HbA1c (38). 
Future large studies are certainly needed to confirm our findings and to evaluate the 
beneficial effects of additional strategies to prevent contrast induced nephropathy in this 
high-risk subgroup of patients.  
Limitations 
Even though the occurrence of contrast induced nephropathy is commonly evaluated at 48 
hours, it may appear even later than this time threshold. Patients with elevated glycated 
haemoglobin had a higher baseline risk profile that may contribute to explain the potential 
association between such a parameter and the risk of CIN. In fact, even though glycated 
haemoglobin resulted to be an indipendet predictor of CIN, statistics can not completely 
overcome the observed differences in baseline characteristics between the groups. We 
observed a similar absolute reduction in creatinine values between baseline and 48 hours in 
the three groups. In fact, we have to realize that hydratation contributed to reduce overall 
values of creatinine, despite the occurrence of CIN in a minority of patients (10 to 15%). 
Therefore, the overall difference in change in creatinine levels among the groups should not 
be considered in the evaluation of association between Glycated haemoglobin and CIN. A 
larger population would have certainly improved our findings. Finally, we were not able to 
provide data on the progression of kidney failure at follow-up, being this disease chronically 
progressive.  
 
 Conclusions  
This is the first study showing that among patients without diabetes undergoing coronary 
angiography or percutaneous interventions elevated glycated haemoglobin but not glucose 
levels is independently associated with the risk of contrast induced nephropathy.  
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Abstract 
Contrast-induced nephropathy (CIN) is a common complication in patients with impaired 
kidney function undergoing coronary angiography/angioplasty. We evaluated whether 
elevated homocysteine (known to be associated with free radical generation and oxidative 
stress) increases the risk of CIN. Patients (n=876) with creatinine clearance <60 ml/min 
undergoing coronary angiography or percutaneous coronary intervention (PCI) were divided 
into tertiles of homocysteine levels. CIN was defined as ≥0.5 mg/dl or ≥25% creatinine 
increase 24-48h post-PCI. A significant relationship was observed between homocysteine 
levels and the risk of CIN (p=0.033), confirmed after correction for baseline confounding 
factors (adjusted odds ratio (OR) [95%CI] =1.68[1.09-2.59], p=0.019). This association was 
also significant applying the new definition of Contrast-Induced Acute Kidney Injury 
(11.9% Group 1, 10.4% Group 2 and 22.8% Group 3; p<0.001), adjusted OR [95% CI] 
 =1.96 [1.3-2.95], p=0.001). Future studies are needed to confirm our findings and to define 
the role of homocysteine in CIN. 
Keywords: Contrast-induced nephropathy, percutaneous coronary intervention, 
homocysteine, creatinine, kidney function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Due to the improvement in pharmacological therapies and mechanical devices1-5, a growing 
number of patients are now revascularized percutaneously, with a larger proportion of high-
risk patients, including those with impaired renal function. Therefore, considerable interest 
has focused on contrast-induced nephropathy (CIN), a common complication associated 
with using contrast media, especially in patients undergoing diagnostic and/or therapeutic 
coronary angiography, where it may occur in up to 20-25% of patients. The development of 
CIN after coronary angiography or angioplasty is associated with poor long-term clinical 
outcome6. Therefore, it is important to identify patients at risk to develop this iatrogenic 
complication and manage them appropriately. The pathogenesis of this condition is the 
result of endothelial dysfunction, cellular toxicity from the contrast agent and tubular 
apoptosis resulting from hypoxic damage or reactive oxygen species7,8. The incidence of 
CIN is related with the presence of risk factors, such as patient-related characteristics (i.e. 
age >75 years, diabetes mellitus, chronic congestive heart failure, or admission with acute 
pulmonary edema, hypotension, anemia and chronic kidney disease) and procedure-related 
characteristics (i.e. the use of elective intra-aortic balloon pump (IABP) or increased 
volumes of contrast media)9. Homocysteine (Hcy) may be a risk factor for 
atherothrombosis, mainly related to endothelial dysfunction, decreased bioavailability of 
nitric oxide and generation of free radicals and oxidative stress10-14, mechanisms that are 
also involved in the occurrence of CIN. It follows that a potential link between elevated 
plasma Hcy levels and the risk of CIN may be hypothesized but has not been extensively 
evaluated. Therefore, we evaluated the association between elevated Hcy and the risk of 
CIN among patients undergoing coronary angiography and/or angioplasty. 
 Methods 
Our population is represented by 1188 consecutive patients with chronic kidney disease 
(CKD; defined as estimated glomerular filtration rate (eGFR) of 60 mL/min or less, as 
calculated by the Cockroft-Gault formula) undergoing coronary angiography and/or 
angioplasty at the Catheterization Laboratory of AOU Maggiore della Carità, Novara, from 
January 2007 to September 2011, who were included in our registry on coronary artery 
disease (CAD). Informed consent was obtained from all patients before angiography. All 
demographic and clinical data were prospectively collected in a dedicated database. 
Hypertension was defined as systolic pressure > 140 mmHg and/or diastolic pressure was 
> 90 mmHg or if the individual was taking antihypertensive medications. The diagnosis of 
diabetes was based on previous history of diabetes treated with or without drug therapies. 
All patients were hydrated with saline solution 1 ml/kg/h 12h before and after the procedure 
or with saline solution 0.5 ml/kg/h (ejection fraction ≤ 40%) or with sodium bicarbonate 
(154 mEq/l in dextrose and water received 3 ml/kg for 1h before contrast exposure followed 
by an infusion of 1 ml/kg/h for 6h after the procedure) for emergency percutaneous 
coronary intervention (PCI). Metformin was discontinued at admission, as were diuretics 
and angiotensin converting enzyme (ACE) inhibitors, with the only exception of patients 
with heart failure.  CIN was defined as an absolute ≥ 0.5 mg/dl or a relative ≥ 25% increase 
in serum creatinine level at 24 or 48h after the procedure. We additionally evaluated CIN 
according to the new Contrast Induced Acute Kidney Injury (CI-AKI) definition15. The 
Mehran risk score for prediction of CIN was calculated as previously described9 
Biochemical measurements                                            
Blood samples were drawn at admission in elective patients (following a fasting period of 
 12h) or urgent coronary angiography16. Glucose, creatinine, hemoglobin, white and red 
blood cells, uric acid and lipid profile were determined by standard methods. Plasma Hcy 
was measured using a competitive immunoassay with direct chemiluminescence detection. 
All the assays were performed on Siemens ADVIA Centaur using ADVIA Centaur HCY 
Ready Pack. The lower detection limit was 0.5 µmol/L. The upper limit for method linearity 
without dilution was 65 µmol/L. The analytical variability was 7%. Creatinine was 
measured at 12, 24 and 48 h after the procedure or longer in case of development of CIN.  
 
Coronary angiography                                                  
Coronary angiography was routinely performed by the Judkins technique using 6-French 
right and left heart catheters through the femoral or radial approach. Quantitative coronary 
angiography (Siemens Acom Quantcor QCA, Erlangen, Germany) was performed by two 
experienced cardiologists who had no knowledge of the patients' clinical information. 
Significant CAD was defined as at least 1 coronary stenosis >50%. Severe multivessel 
disease was defined as 3-vessel disease and/or left main disease17. The contrast medium 
used was non-ionic, iso-osmolar (Optiray-Ioversolo, 350 mg/ml, Visipaque-Iodixanolo, 320 
mg l/ml or Ultravist-Iopromide, 370 mg/ml). 
Statistical analysis 
Statistical analysis was performed using the SPSS 15.0 statistical package. Continuous data 
were expressed as mean + SD and categorical data as percentage. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. A trend 
analysis was performed as previously described18. Multiple logistic regression analysis was 
performed to evaluate the relationship between Hcy and CIN, after correction for baseline 
 confounding factors (clinical and demographic variables with a two-sided p < 0.05), that 
were entered in the model in block.  
Table 1. Baseline Clinical Characteristics. 
Variable Group 1 
Homocysteine <  
15.3 μmol/L            
Group 2 
Homocysteine  
15.3.21.7 
μmol/L            
Group 3 
Homocysteine  
> 21.7 μmol/L            
P  
Demographic  and clinical 
characteristics 
    
Age (years) (Mean ± SD) 75.2 + 7 75.3 + 7.8 76.3 + 6.6 0.059 
Male Sex (%) 45.8 57.6 65.7 <0.001 
Hypertension (%) 74 78.1 81.5 0.031 
Smoking (%) 10.8 16.1 17.2 0.058 
Hypercholesterolemia (%) 55.7 54.7 50 0.17 
Diabetes (%) 39.3 36.1 39.5 0.93 
Family history of CAD (%) 27.8 17.2 19.3 0.015 
Previous AMI (%) 27.4 27.7 33.3 0.11 
Previous PCI (%) 17.5 23.2 21.8 0.22 
Previous CABG (%) 17.2 17.6 19.5 0.46 
Previous CVA (%) 8.8 12.6 12.5 0.16 
Indication for angiography    0.019 
Stable angina or silent ischemia (%) 8.7 11.4 9.2  
Acute Coronary Syndrome (%) 75.8 62.4 63.7  
DCM or valvular disease (%) 15.5 26.2 27.1  
Baseline Chemistry     
White blood cell count (10^5/ml) 
(Mean ± SD) 
8.0 + 4 7.9 + 3.7 7.5 + 2.1 0.13 
Red blood cell count (10^6/μl) 
(Mean ± SD) 
4.3 + 0.5 4.4 + 0.6 4.3 + 0.5 0.45 
Hemoglobin levels (g/dL) (Mean ± 
SD) 
12.6 + 1.5 12.7 + 1.7 12.6 + 1.9 0.65 
Platelet count (10^5/ml) (Mean ± 
SD) 
215 + 68 217 + 65 214 + 72 0.92 
Fibrinogen (mg/dL) (Mean ± SD) 473 + 156 487 + 156 492 + 143 0.14 
Glycemia (mg/dL) (Mean ± SD) 136 + 62 123 + 42 130 + 59 0.15 
Glycosylated Hemoglobin 
(%)(Mean ± SD) 
6.3 + 1.2 6.3 + 1.1 6.3 + 1.3 0.92 
Basal creatinine (mg/dL) (Mean ± 
SD) 
1.1 + 0.33 1.3 + 0.3 1.5 + 0.5 <0.001 
 
eGFR (ml/min) (MDRD) 58.6 + 14.8 53.9 + 13.9 47.9 + 15.4 <0.001 
eGFR (ml/min) (MDRD) 24h 63.5 +  27.7  55.6 + 14.9 51.5 + 17.6 <0.001 
eGFR (ml/min) (MDRD) 48h 55.7 + 21.6 51 +  15.6 45.5 + 19.1 <0.001 
Total-cholesterol (mg/dL) (Mean + 156 + 38 157 + 38 157 + 40 0.70 
 SD) 
HDL-Cholesterol (mg/dL) (Mean ± 
SD) 
40 + 11 40 + 13 39 + 13 0.20 
Triglycerides (mg/dL) (Mean ± SD) 129 + 66 138 + 79 145 + 76 0.012 
LDL-Cholesterol (mg/dL) (Mean ± 
SD) 
90 + 33 91 + 32 91 + 33 0.76 
Treatment at admission     
ACE Inhibitor (%) 57.1 60.8 56.8 0.91 
Angiotensin-receptor blockers (%) 21.3 22.8 26.4 0.15 
Statins (%) 51.3 51.3 40.6 <0.001 
Nitrate (%) 47.3 44 47.5 0.93 
Beta-blockers (%) 48 51 49.2 0.79 
Aspirin (%) 55.6 61.1 57.8 0.62 
Clopidogrel (%) 42.4 41.2 30.1 0.014 
Calcium Antagonist (%) 20.9 26.5 27.4 0.076 
Diuretics (%) 35.4 45.3 51.2 <0.001 
Procedural characteristics     
Coronary Angioplasty 45.4% 42.9% 43.3% 0.63 
Contrast Volume (ml)  
(Mean ± SD) 
216 + 145 206 + 136 218 + 147 0.59 
Contrast Volume (CA) (ml)  
(Mean ± SD) 
138.8 + 66.2 147.6 + 86.6 141.3 + 86.8 0.60 
Contrast Volume (PCI) (ml)  
(Mean ± SD) 
322.9 + 158 269 + 139.4 327.6 + 152 0.50 
Mehran Risk Score 11 + 4 10.8 + 4.5 12.2 + 4.2 <0.001 
Risk of CIN  24.2 + 14.6 24.5 + 16.1 28.4 + 16.6 0.002 
CAD = Coronary artery disease; AMI = Acute Myocardial Infarction; PTCA = Percutaneous Transluminal 
Coronary Angioplasty; CABG: Coronary Artery Bypass Grafting; CVA = Cerebrovascular Accident; DCM 
= Dilated Cardiomyopathy; ACE = angiotensin converting enzyme; LDL = low density lipoprotein; HDL = 
high density lipoprotein; eGFR = estimated glomerular filtration rate; CA = coronary angiography; PCI = 
percutaneous coronary intervention 
 
Results 
Our initial population included 1188 consecutive patients with CKD. A total of 312 were 
excluded because of the following reasons: 136 patients because serial serum creatinine 
measurements (at baseline, 24 or 48h) were not available; 49 patients for end stage renal 
failure requiring dialysis and 127 patients because of unavailability of serum Hcy levels. 
Therefore, our final study population included 876 patients. 
 Baseline clinical characteristics, indication for angiography, procedural characteristics, 
baseline chemistry and admission therapy, according to tertiles (Group 1, <15.3; Group 2, 
15.3-21.7, Group 3 >21.7 μmol/l) of plasma Hcy levels, are listed in Table 1. 
Patients with higher Hcy levels were predominantly males (p < 0.01), with higher 
prevalence of hypertension (p = 0.031), higher baseline creatinine (p < 0.01), lower eGFR at 
baseline (p < 0.01) and higher triglycerides (p < 0.01), but with lower prevalence of family 
history of CAD (p = 0.015). In addition, elevated Hcy was more often associated with 
dilated cardiomyopathy/valvular disease as indication for angiography (p = 0.019) and 
diuretics at admission (p < 0.001), but less often were on statins (p < 0.001) and clopidogrel 
(p = 0.014) at admission. No differences were found in any other biochemical parameters, 
clinical characteristics, treatment or procedural characteristics, and contrast agent volume 
(both in case of coronary angiography alone or followed by PCI). Of the 116 out of the 876 
patients developed CIN (13.2%); the incidence of CIN was significantly different among 
groups (17.5% in Group 3 vs 10.4% in Group 2 and 11.6% in Group 1; p=0.033) (Figure 1).  
Figure 1. Bar graph showing the relationship between homocysteine and the risk of contrast-
induced nephropathy. 
 
 The association between elevated Hcy levels (third tertile) and the occurrence of CIN was 
confirmed by multivariate analysis after correction for baseline confounding factor  (gender, 
hypertension, family history of CAD, basal creatinine, creatinine clearance, triglycerides, 
statins, clopidogrel and diuretics, dilated cardiomyopathy or valvular disease as indication 
for angiography and Mehran Risk Score) (adjusted OR [95% CI] = 1.68 [1.09-2.59], p = 
0.019). The association between elevated Hcy levels and the occurrence of CIN was 
confirmed also when applying the new definition of CI-AKI according to current K-DIGO 
(Kidney Disease Improving Global Outcomes) guidelines (11.9% Group 1, 10.4% Group 2 
and 22.8% Group 3; p < 0.001), and after correction for baseline confounding factors 
(adjusted OR [95% CI] = 1.96 [1.3-2.95], p = 0.001).  
Discussion 
Our main finding is that elevated Hcy is independently associated with the risk of CIN 
among patients with impaired renal function undergoing coronary angiography and/or 
angioplasty. Due to the great improvement in pharmacological therapy and interventional 
procedures, most of the patients with CAD are currently revascularization percutaneously, 
especially in the setting of acute coronary syndromes 19-23, with a growing proportion of 
high-risk patients, including those with impaired renal function5. Considerable interest has 
focused on the risk of CIN, which is a common complication among patients undergoing 
coronary angiography and/or angioplasty. In fact, the higher complexity of patients 
currently undergoing angioplasty implies the presence of more clinical risk factors for such 
a complications, in addition to use of larger amount of contrast media24. Several studies 
have described an occurrence of CIN in up to 20-25% of interventions9. Advanced age, 
 diabetes, poor renal function, use of diuretics, oral antidiabetic therapies, cardiogenic shock 
and the amount of contrast media, are some of the recognized risk factors for such a 
complications25. In 2004 Mehran et al9 proposed a CIN risk stratification score based on 8 
readily available variables to better identify patients at high risk of CIN. In fact, the 
identification of subjects at high-risk for CIN and the identification of new pre-treatment 
strategies beyond hydration, administration with acetylcysteine26-27, is of extreme 
importance in order to reduce the risk of this complication and to further improve clinical 
outcome of patients undergoing such a procedure. The pathogenesis of CIN is the result of 
endothelial dysfunction, cellular toxicity from the contrast agent and tubular apoptosis 
resulting from hypoxic damage or reactive oxygen species. In patients with CKD, identified 
by an eGFR <60 ml/min/1.73m2 there is a loss of nephron units and residual renal function 
is vulnerable to decline. Contrast agents may trigger the release of endothelin and adenosine 
from endothelial cells, increasing vasoconstriction, and decrease the release of 
prostaglandins, preventing vasodilatation, thus decreasing oxygen in the outer medulla. In 
fact, adenosine can have a vasoconstrictor effect in the afferent arteriole, unlike the 
vasodilatation it causes in larger arterioles located in the coronary and peripheral 
vasculature28,29. Hcy is metabolized by the kidney, so its plasma levels are correlated with 
renal function (Hcy levels are 2 to 4-fold higher in patients with CKD)10-14. Experimental 
studies have shown that hyperhomocysteinemia is associated with elevated risk of 
atherosclerosis and vascular damage, mediated by endothelial dysfunction, decreased 
bioavailability of nitric oxide, generation of free radicals and oxidative stress11. On the basis 
of these assumptions an association between hyperhomocysteinemia and the occurrence of 
CIN may be conceivable. So far only one study 30 has investigated the relationship between 
 Hcy and the risk of CIN. In a population of 572 patients undergoing PCI, the incidence of 
CIN was significantly greater in patients in the third Hcy tertile (24.2 vs 4.7% in the first 
and 7.3% in the second tertile, p < 0.001). In our study, the largest so far, we included 872 
patients, undergoing coronary angiography and/or intervention. Differently from Seung et 
al30, we included patients undergoing coronary angiography and/or angioplasty, but focused 
only on patients with baseline impaired renal function. Like Seung et al30, we divided our 
population into Hcy tertiles and found a significantly higher occurrence of CIN in the third 
tertiles (> 21.7 μmol/L) as compared with patients in the second (15.3-21.7 μmol/L) and 
first tertile (< 15.3 μmol/L) (17.5, 10.4 and 11.6%, p = 0.033). The relationship between 
elevated Hcy and the risk of CIN was confirmed at multivariate analysis after correction for 
baseline confounding factors. The association between elevated Hcy levels and the 
occurrence of CIN was similarly observed when applying the new CI-AKI definition 
according to current K-DIGO guidelines15. The association was confirmed at multivariate 
analysis after correction for baseline confounding factors, including the Merhan Risk Score. 
Future large studies are needed to confirm our findings. Lowering Hcy levels has not been 
proven to reduce cardiovascular events31. However, due to safety and low costs of vitamin-
based Hcy-lowering therapy32,33, future randomized trials are needed to evaluate whether in 
an elective context, Hcy-lowering therapy (e.g. started in the week before the procedure) 
may lower the risk of CIN among patients with elevated Hcy and impaired renal function 
undergoing coronary angiography and/or angioplasty.  
 
 
 Limitations 
Our population is represented by patients with impaired renal function (creatinine clearance 
< 60 ml/min). CKD is the most important risk factor for the development of CIN, and the 
vast majority of trials focus on this kind of population for the evaluation preventive 
strategies, like hydration and N-acetylcysteine administration. This decision also allowed us 
to have a more homogeneous population. Patients of the Third Tertile were more often on 
statins at admission and several studies in literature evaluated the protective effects of 
statin34-36 therapy on the risk of CIN. However our results were confirmed after correction 
for all baseline confounding factors, including pretreatment with statins. Even though the 
occurrence of CIN is commonly evaluated at 48 h, it may appear even later than this time 
limit. Furthermore, we were not able to provide data on the progression of kidney failure at 
follow-up, although this disease may be chronically progressive. Finally, hydration and N-
acetylcysteine has been shown to reduce Hcy levels37. However, all patients in the 3 groups 
underwent adequate hydration protocols and therefore this would not have affected our 
results.  
Conclusions  
This is the first large study showing that elevated Hcy is a risk factor for CIN and therefore 
more attention should be paid to these patients in order to provide optimal hydration and 
minimize contrast volume. Future randomized trials are needed to address whether in an 
elective context, lowering Hcy levels with vitamins may reduce the risk of CIN among 
patients with elevated Hcy.  
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Abstract 
Background. Contrast Induced Nephropathy (CIN) is a common complication of 
procedures that foresee the use of contrast media that seems to be mediated by oxidative 
stress and reactive oxygen species generation. Hyperuricemia is characterized by inhibited 
nitric oxide system and enhanced synthesis of reactive oxygen species. However, few 
studies have so far investigated the association between hyperuricemia and CIN that is 
therefore the aim of the current study among patients undergoing coronary angiography or 
percutaneous intervention. 
Methods. We analyzed a total of 1950 patients with Creatinine clearance <90ml/min) 
undergoing elective or urgent coronary angiography and/or angioplasty. Patients were 
divided according to tertiles of baseline uric acid (Group1, < 5.5mg/dL n= 653; Group2, 
5.6-7.0 mg/dL, n=654; Group 3, > 7.0 mg/dL, n=643). CIN was defined as an absolute ≥ 
 0,5mg/dl or a relative ≥ 25% increase in the serum creatinine level at 24 or 48h after the 
procedure. 
Results. Patients with higher uric acid levels were older, previous smokers, with higher 
prevalence of hypertension and diabetes, but with lower family history of CAD. They had 
more often history of a previous CABG and baseline renal dysfunction. Patients of the third 
Tertile had also higher levels of white blood cells, higher triglycerides and lower HDL-
cholesterol and higher percentage of dilated cardiomyopathy/valvular disease as indication 
for angiography and consequently a lower prevalence of PCI. Patients with higher SUA 
were more often on therapy with ACE inhibitors and diuretics, but less often with statins, 
nitrate, ASA and Clopidogrel at admission. The occurrence of CIN was observed in 251 
patients (12.9%), and was significantly associated with uric acid levels (12.3% in Group 1, 
10.4% in Group 2 and 16.0% in Group 3; p=0.04). Similar results were observed when the 
analysis was performed according to each tertiles values in both male and female gender. 
The association between elevated uric acid (> 7 mg/dl) and CIN was confirmed by 
multivariate analysis after correction for baseline confounding (Adjusted OR [95%CI] = 
1.42 [1.04-1.93], p=0.026). Similar results were observed across major subgroups of high-
risk patients, such as patients with diabetes, female gender, renal failure, hypertension, and 
elderly. 
Conclusions. This is the first large study showing that among patients undergoing coronary 
angiography or percutaneous interventions elevated uric acid level is independently 
associated with an increased risk of CIN. 
 
 Keywords: Uric acid; contrast induced nephropathy 
 
Introduction 
Contrast Induced Nephropathy (CIN) is one of the most common complications of 
procedures that foresee the use of contrast media (1,2) and is commonly defined as an 
increase in serum creatinine levels, usually more than 0,5mg/dl or 25% of baseline levels, 
within 24-48h after contrast exposure. The development of CIN after coronary angiography 
or angioplasty is associated with a poor long-term clinical outcome and in particular patients 
who developed acute renal failure and required dialysis after PCI have a 40% in-hospital 
mortality and about an 80% 2-year mortality rate (3). In patients undergoing diagnostic 
and/or therapeutic coronary angiography CIN has shown to occur in up to 20-25% 
depending on the presence of known risk factors, such as chronic kidney disease, diabetes 
mellitus, accompanying hypotension, high dose of contrast medium, congestive heart 
failure, advanced age and anemia (4,5). In recent years, due to the improvement in device 
technology (6-8) and antithrombotic therapies (9-11), a yearly growing number of patients 
is now revascularized percutaneously, especially for acute myocardial infarction, with a 
larger proportion of high-risk patients, including those with impaired renal function. The 
pathogenesis of CIN is the result of endothelial dysfunction, cellular toxicity from the 
contrast agent and tubular apoptosis resulting from hypoxic damage or reactive oxygen 
species (12). The use of contrast media superimposed acute vasoconstriction, caused by the 
release of adenosine and endothelin, with the reduction in renal blood flow to the outer 
 medulla, consequent medullary hypoxia, ischemic injury and death of renal tubular cells 
(13). 
Serum uric acid (SUA), a degradation metabolite of purines, has been extensively addressed 
in the past years as a possible risk factor for cardiovascular disease (14).  
Hyperuricemia is characterized by inhibited nitric oxide system, activation of the local 
rennin-angiotensin system, pro-inflammatory and proliferative actions and enhanced 
synthesis of reactive oxygen species with increased oxidative stress and consequent renal 
dysfunction (15,16). These effects of hyperuricemia should be more evident in patients with 
chronic kidney disease, in which there is a loss of nephron units with a poor residual renal 
function more vulnerable to external insults. So far few studies have investigated the role of 
uric acid in the occurrence of CIN. Therefore, the aim of the current study was to evaluate 
whether high level of serum uric acid in patients undergoing elective coronary angiography, 
percutaneous intervention or urgent PCI, is associated with an increased risk of CIN. 
Material and Methods 
Our population is represented by consecutive 1950 patients with estimated glomerular 
filtration rate (GFR) of 89 mL/min or less, as calculated by applying the Cockroft-Gault 
formula) (17) undergoing coronary angiography and/or angioplasty at Catheterization 
Laboratory of AOU Maggiore della Carità, Novara, from January 2007 to September 2011, 
who were included in our registry on coronary artery disease protected by password. 
Informed consent was obtained by all patients before angiography. Hypertension was 
defined as systolic pressure > 140 mm Hg and/or diastolic pressure > 90 mm Hg or if the 
individual was taking antihypertensive medications. All patients with creatinine clearance 
 <60ml/min were hydrated with saline solution 1ml/kg/h 12h before and after the procedure 
or with saline solution 0.5ml/kg/h, if ejection fraction ≤ 40% or with sodium bicarbonate 
(154 mEq/l in dextrose and water received 3 ml/kg for 1h before contrast exposure followed 
by an infusion of 1 ml/kg/h for 6h after the procedure) for emergency PCI. CIN was defined 
as an absolute ≥ 0.5mg/dl or a relative ≥ 25% increase in the serum creatinine level at 24 or 
48h after the procedure. 
Biochemical measurements 
Blood samples were drawn at admission in patients undergoing elective (following a fasting 
period of 12 h) or urgent coronary angiography. Glucose, creatinine, uric acid, blood cells 
count and lipid profile were determined by standard methods. 
Creatinine was measured at 12, 24 and 48 hours after the procedure or longer in case of 
development of CIN.  
Coronary angiography 
Coronary angiography was routinely performed by the Judkins technique using 6-French 
right and left heart catheters through the femoral or radial approach. Quantitative coronary 
angiography (Siemens Acom Quantcor QCA, Erlangen, Germany) was performed by two 
experienced cardiologists who had no knowledge of the patients' clinical information. 
Significant coronary artery disease was defined as at least 1 coronary stenosis more than 
50%. The contrast medium used was non-ionic, iso-osmolar (Optiray-Ioversolo, 350mg/ml, 
Visipaque-Iodixanolo, 320mg l/ml, Ultravist-Iopromide, 370mg/ml). 
 
 
 Statistical analysis 
Statistical analysis was performed with the SPSS 15.0 statistical package. Continuous data 
were expressed as mean + SD and categorical data as percentage. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. A trend 
analysis was performed as previously described (18). Multiple logistic regression analysis 
was performed to evaluate the relationship between serum uric acid levels and CIN, after 
correction for baseline confounding factors (clinical and demographic variables with a p 
value < 0.05), that were entered in the model in block. 
Results 
We analyzed a total of 2025 patients with chronic kidney disease undergoing coronary 
angiography and/or angioplasty. A total of 75 patients were excluded because of end stage 
renal failure requiring dialysis or because baseline uric acid levels were not available. 
Therefore our final study population was represented by 1950 patients. Patients were 
divided according to tertiles of baseline serum uric acid (Group1, < 5.5mg/dL n = 653; 
Group2, 5.6-7.0 mg/dL, n = 654; Group 3, > 7.0 mg/dL, n = 643). Patient’s baseline clinical 
and demographic characteristics, indication for angiography, procedural main 
characteristics, baseline chemistry and admission therapy, according to the tertile of serum 
uric acid levels, are listed in Table 1.  
 
 
 
 
 
 Table 1. Baseline Clinical Characteristics according to uric acid levels 
Variable 1° Tertile 
< 5.5 mg/dL 
 (n = 653) 
2° Tertile 
5.6-7.0 mg/dL 
 (n = 654) 
3° Tertile 
>7 mg/dL 
 (n = 643) 
p-value 
Demographic  and clinical 
characteristics 
    
Age (M-SD) 71.6+/-9.1 72+/-8.7 72.8+/-8.4 0.01 
Age > 75 (%) 42.6 41.3 48.2 0.04 
Hypertension (%) 72 73.1 82.1 <0.001 
Smokers (%)    0.03 
Active smokers (%) 35.2 33.3 32.3  
Previous smokers (%) 49.6 57.4 57.5  
Hypercolesterolemia (%)     
Diabetes (%) 31.9 37.8 42.9 <0.001 
Family history of CAD (%) 28.2 25.7 22.6 0.02 
Previous AMI (%) 26.2 26.8 27.2 0.67 
Previous PCI (%) 21.9 24.2 20.4 0.51 
Previous CABG (%) 13.6 14.4 18 0.03 
Previous CVA (%) 8.7 8.4 9.6 0.57 
Cr. Clearance<60ml/min 
(%) 
45.8 50.3 68.4 <0.001 
Indication for 
angiography 
   <0.001 
Stable angina or silent 
ischemia (%) 
28 29.5 20.7  
Acute Coronary Syndrome 
(%) 
55.9 52.9 48.5  
DCM or valvular disease 
(%) 
16.1 17.6 30.8  
Baseline Chemistry     
White blood cells (M-SD) 7.4+/-3.1 7.9+/-4 8+/-2.7 <0.001 
Red blood cells (M-SD) 4.4+/-0.5 4.5+/-0.5 4.5+/-0.6 0.46 
Haemoglobin (M-SD) 13.1+/-1.6 13.2+/-1.6 13.1+/-1.9 0.58 
Platelet (M-SD) 216.2+/-62.7 214.1+/-72 218.9+/-72.2 0.5 
Glycaemia at admission 
(M-SD) 
127.2+/-49 123.07+/-42 131.8+/-59 0.1 
Total Cholesterol (M-SD) 158.7+/-39.9 159.3+/-39.7 159.2+/-39.1 0.84 
HDL-Cholesterol (M-SD) 43.4+/-13.4 40.4+/-12.2 38.6+/-13 <0.001 
Triglycerides (M-SD) 126.6+/-62.8 138.8+/-77.8 154.1+/-101.7 <0.001 
LDL-Cholesterol (M-SD) 90.5+/-35.2 91.7+/-33.3 91.3+/-32.4 0.7 
Theraphy at admission     
ACE I (%) 36.6 42 42.6 0.03 
ARB (%) 21.7 20.9 22.9 0.63 
Statins (%) 52.8 52.4 44.2 0.002 
Nitrate (%) 44 41 36.9 0.009 
Beta-Blockers (%) 53.8 52.3 50.7 0.27 
ASA (%) 62 61.6 53.8 0.003 
 Clopidogrel (%) 24.7 24.2 20.1 0.05 
Ticlopidine (%) 9.5 6.9 8.4 0.47 
Calcium Antagonist (%) 21.7 20.8 26.1 0.06 
Diuretics (%) 24.7 32.6 51.8 <0.001 
Allopurinol (%) 5.5 4.7 5.4 0.95 
Procedural 
characteristics 
    
PCI (%) 49.2 49.8 42 0.01 
Contrast Agent (M-SD) 229+/-144 231+/-143.4 219.4+/-147.9 0.25 
M = Mean; SD = Standard Deviation; CAD = coronary artery disease; AMI = acute myocardial infarction; 
PCI = percutaneous coronary intervention; CABG = coronary artery by-pass graft; CVA = cardiovascular 
accident; DCM= dilated cardiomyopathy;  HDL =  high density lipoprotein; LDL = low density lipoprotein; 
ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blockers; ASA = acetylsalicylic acid 
 
Patients with higher uric acid levels were older (p=0.01), more often previous smokers 
(p=0.03), with higher prevalence of hypertension (p<0.001) and diabetes (p<0.001), but 
with lower family history of CAD (p=0.02). They had more often history of previous CABG 
(p=0.03) and baseline renal dysfunction (Creatinine clearance <60ml/min,  p<0.001). 
Patients of the third Tertile had also higher levels of white blood cells (p<0.001), higher 
triglycerides (p<0.001) and lower HDL-cholesterol (p<0.001) and higher percentage of 
dilated cardiomyopathy/valvular disease as indication for angiography (p<0.001) and 
consequently a lower prevalence of PCI (p=0.01). Patients with higher SUA were more 
often on therapy with ACE inhibitors (p=0.03) and diuretics (p<0.001), but less often with 
statins (p=0.002), nitrate (p=0.009), ASA (p=0.003) and Clopidogrel (p=0.05) at admission.  
No differences were found in any other biochemical parameters, clinical characteristics, 
therapy (in particular regarding use of uric acid lowering therapy) or procedural 
characteristics, and contrast agent volume (both in case of coronary angiography alone or 
followed by PCI).  
 
 Figure 1. Bar graph showing the relationship between uric acid level and the risk of contrast-
induced nephropathy in all patients (Graph A), in women (Graph B) and men (Graph C). 
 
CIN was observed in 251 patients (12.9%), and was significantly associated with uric acid 
levels (12.3% in Group 1, 10.4% in Group 2 and 16.0% in Group 3; p=0.04, Figure 1A). 
Similar results were observed when the analysis was performed according to each tertiles 
values in both female and male gender (Figures 1B-1C). The association between elevated 
uric acid (> 7 mg/dl) and CIN was confirmed by multivariate analysis after correction for 
baseline confounding factors (age, hypertension, smoking, diabetes, previous CABG, 
creatinine clearance <60ml/min, family history of CAD, white blood cells, HDL-
cholesterol, triglycerides, ACE inhibitors, ASA, Clopidogrel, Statins, Nitrate and Diuretics, 
dilated cardiomyopathy or valvular disease as indication for angiography) (Adjusted OR 
 [95%CI] = 1.42 [1.04-1.93], p=0.026). In fact, as shown in Figure 2, consistent results were 
observed across major subgroups of high-risk patients, such as patients with diabetes, renal 
failure, hypertension, age>75. 
Figure 2. Relationship between glycated haemoglobin levels and the risk of contrast induced 
nephropathy (CIN) in major subgroups of patients according to gender, age,  hypertension, baseline 
renal failure and diabetes. 
 
Discussion 
The main finding of our study is that in patients undergoing coronary angiography or 
percutaneous interventions, serum uric acid level is independently associated with an 
increased risk of CIN. Coronary artery disease is still the first cause of mortality in 
developed countries. However, a larger application of revascularization procedures, 
especially in the setting of acute myocardial infarction (19, 20), has contributed to the 
relevant reduction in mortality observed in the last decades. Due to the improvement in stent 
 technology (6-8), a yearly growing number of patients undergo percutaneous 
revascularization, with a larger proportion of high-risk patients, including those with 
impaired renal function. The development of CIN is associates with increased mortality and 
morbidity rate and is a costly complication (3). Several mechanism have been suggested as 
etiologic factors for CIN, such as chronic kidney disease, diabetes mellitus, accompanying 
hypotension, high dose of contrast medium, congestive heart failure, advanced age and 
anemia (4, 5). The pathophysiology of CIN is complex and multifactorial (21). Injury starts 
with a critical illness affecting the kidneys, then a contrast agent causes direct cytotoxicity 
to renal tubular cells because of water solubility. The use of contrast media superimposed 
acute vasoconstriction, caused by the release of adenosine and endothelin, with the 
reduction in renal blood flow to the outer medulla, consequent medullary hypoxia, ischemic 
injury and death of renal tubular cells (12). Prevention is the key to reduce the incidence of 
CIN and it begins with the identification of the high risk patient coupled with appropriate 
periprocedural management (hydratation and administration with acetylcysteine) (22). 
Serum uric acid is the final product of purine metabolism, so hyperuricemia may occur 
because of decreased excretion, increased production or a combination of these two 
mechanism (23). Hyperuricemia is characterized by inhibited nitric oxide system, activation 
of the local rennin-angiotensin system, pro-inflammatory and proliferative actions and 
enhanced synthesis of reactive oxygen species with increased oxidative stress and 
consequent renal dysfunction (16). These effects should be more evident in patients with 
chronic kidney disease, in which there is a loss of nephron units with a residual renal 
function more vulnerable to external insults. Several studies in literature have shown that 
elevated uric acid level is associated with cardiovascular events, stroke and with the 
 development of chronic kidney disease in type II diabetes mellitus (24). On the other side 
uric acid has antioxidant properties, which are both direct and indirect: it acts by promoting 
superoxide dismutase activity, by removing peroxynitrite and O2 and by strengthening the 
antioxidant action of ascorbate with a reduction of lipid peroxidation.  It  was demonstrated 
that subjects with atherosclerosis had higher serum antioxidant capacity than matched 
controls (25). Furthermore, uric acid seems to restore endothelial function in type 1 diabetes 
(2). In fact, we previously found no association between uric acid and the extent of CAD 
(26). On the basis of this assumptions it might be supposed that the role of uric acid in the 
development of CIN could potentially represent an association with a complex clinical 
condition. Few studies has so far investigated the role of hyperuricemia as a predictor of 
CIN. Two studies in the past evaluated the relationship between contrast agents and uric 
acid, showing that contrast agents have a uricosuric effect caused by enhanced renal tubular 
secretion of uric acid with possible nephrotoxic effect (27,28). 
Toprak et al. (29) showed that, among 266 patients undergoing coronary angiography, there 
was a significantly higher incidence of CIN in the hyperuricemic group (15.1%) vs 
normouricemic group (2.9%). Elevated SUA has been reported in literature as an 
independent predictor of CIN in STEMI patients who underwent primary PCI (15). Two 
recent studies, (14, 30), the first retrospective and the second prospective, showed that 
STEMI patient (744 and 835, respectively) who underwent primary PCI and developed CIN 
(incidence 12.5% and 9.6%respectively) had higher level of uric acid in comparison to  
patients who did not develop CIN. This is the largest study so far conducted to investigate 
the potential association between elevated uric acid and the occurrence of CIN. Our 
population was represented by patients with impaired renal function that is known as the 
 most important risk factor for the development of CIN. We found an occurrence of CIN of 
12.9%, with a significant correlation with uric acid levels, that was confirmed at 
multivariate analysis after correction for all baseline confounding factors. Similar results 
were observed when the analysis was performed according to each tertiles values in both 
female and male gender and across major subgroups of high-risk patients, such as patients 
with diabetes, renal failure, hypertension, age>75. Future studies are certainly needed to 
confirm our findings and to evaluate the beneficial effects of uric acid reduction and 
additional strategies to prevent CIN in this high-risk subgroup of patients. 
Limitations 
Even though the occurrence of CIN is commonly evaluated at 48 hours, it may appear even 
later than this time threshold. Furthermore, we were not able to provide data on the 
progression of kidney failure at follow-up, being this disease chronically progressive. 
Conclusions  
This is the first large study showing that among patients undergoing coronary angiography 
or percutaneous interventions elevated uric acid level is independently associated with the 
risk of CIN.  
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Abstract 
Background. Contrast Induced Nephropathy (CIN) is a common complication of coronary 
angiography/angioplasty. Prevention is the key to reduce the incidence of CIN and it begins 
with appropriate pre-procedural management. Statins have been shown to possess 
pleiotropic effects (anti-oxidant, anti-inflammatory and anti-thrombotic properties) and their 
effects on CIN were assessed in several studies with conflicting results. Aim of this meta-
analysis is to evaluate the efficacy of short-term statins for the prevention of CIN in patients 
undergoing coronary angiography/percutaneous interventions. 
Methods. We performed formal searches of PubMed, EMBASE, Cochrane central register 
of controlled trials and major international scientific session abstracts from January 1990 to 
January 2014 of trials which compares short-term statins versus Placebo for the prevention 
of CIN in patients undergoing coronary angiography/angioplasty. Data regarding study 
design, statin dose, inclusion/exclusion criteria, number of patients, and clinical outcome 
was extracted by 2 investigators. 
 Results. Eight trials were included, with a total of 4734 patients. CIN occurred in 79/2358 
patients (3.3%) treated with statins versus 153/2376 patients (6.4%) of the placebo group 
(OR[95%CI]=0.50[0.38-0.66],p<0.00001;phet=0.39). Benefits were both observed with 
high-dose short-term statins (OR[95%CI]=0.44[0.30-0.65],p<0.0001;phet=0.16) and low-
dose statins, (OR[95%CI]=0.58[0.39-0.88],p=0.010;phet=0.90). By meta-regression analysis, 
no significant relationship was observed between benefits from statin therapy and patient’s 
risk profile (p=0.26), LDL cholesterol (p = 0.4), contrast volume (p = 0.94) or diabetes rate 
(p = 0.38).  
Conclusions. This meta-analysis showed that among patients undergoing coronary 
angiography/percutaneous intervention the use of short-term statin reduces the incidence of 
CIN, and therefore is highly recommended even in patients with low LDL-cholesterol 
levels. 
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 INTRODUCTION 
Contrast-induced nephropathy (CIN) is a common complication of procedures that foresee 
the use of contrast media and is defined as an increase in serum creatinine levels more than 
0,5mg/dl or 25% of baseline levels, within 24-48 hours after the procedure (1,2). CIN is the 
third leading cause of hospital-acquired acute renal injury, accounting for 11% of all cases 
(3) and in patients undergoing diagnostic and/or therapeutic coronary angiography, it has 
shown to occur in up to 20-25% depending on the presence of known risk factors, such as 
chronic renal insufficiency, diabetes mellitus and the dose of contrast medium (4,5). Due to 
the improvement in stent technology (6-10), a yearly growing proportion of patients is now 
revascularized percutaneously, with a larger proportion of high-risk patients, including those 
with impaired renal function that is the most important risk factor for the development of 
CIN. Therefore, large interest has been focused in the last years on this iatrogenic 
complication. Several therapies for the prevention of CIN, such as different hydration and 
alkalinization measures (11-12), N-acetylcysteine (NAC) (13), Fenoldopam, hemodyalisis 
and hemofiltration (14-16) have been explored in randomized clinical trials (17-18), leading 
to conflicting results. The pathogenesis of CIN is the result of endothelial dysfunction, 
cellular toxicity from the contrast agent and tubular apoptosis resulting from hypoxic 
damage or reactive oxygen species (1), therefore, pharmacological prophylactic strategies 
based on antioxidant properties have received considerable attention.  
Statins have been shown to possess endothelial protective properties potentially preventing 
contrast induced nephropathy (19-20). A large number of studies in the last decades have 
evaluated the role of statins for the prevention of CIN in patients undergoing coronary 
angiography or percutaneous interventions with conflicting results (21-25). Therefore, aim 
 of the current meta-analysis is to assess the effectiveness of short term statin treatment for 
the prevention of CIN in patients undergoing coronary angiography or percutaneous 
interventions. 
 
METHODS 
Eligibility and search strategy. We conducted a search of PubMed, EMBASE, Cochrane 
central register of controlled trials and major international scientific session abstracts from 
January 1990 to January 2014 regarding the role of Statin for the prevention of CIN in 
patients undergoing coronary angiography or percutaneous interventions. Furthermore, oral 
presentations and/or expert slide presentations were included, searched on EuroPCR 
(www.europcr.com), ACC (www.acc.org), AHA (www.aha.org), and ESC 
(www.escardio.org) websites from January 2000 to January 2014. The following key words 
were used: “statin and CIN”, “acute kidney injury”, “contrast induced nephropathy”, 
“Atorvastatin”, “Rosuvastatin”, “Simvastatin”, “Pravastatin”, “acute coronary syndrome”, 
“coronary angiography”, “percutaneous interventions”. We included randomized controlled 
trials which compared a preventive strategy with short-term statin versus placebo for the 
prevention of contrast induced nephropathy in patients undergoing coronary angiography or 
percutaneous interventions. Studies comparing high-dose statins versus low-dose statins 
were excluded. We did not restrict eligibility according to kidney function.  
Data extraction and validity assessment. Data were independently abstracted by two 
investigators, with a good agreement (κ statistic = 0.89). Disagreements were resolved by 
consensus. Data were managed according to the intention-to-treat principle. 
 Outcome measures. Primary endpoint was the development of CIN, defined as an increase 
of serum creatinine >0,5mg/dL or >25% within 48 to 120 hours after the exposure to 
contrast medium. 
Data analysis. Statistical analysis was performed using the Review Manager 4.27 freeware 
package, SPSS 17 statistical package. Odds ratio (OR) and 95% confidence intervals (95% 
CI) were used as summary statistics. The pooled odds ratio was calculated by using a fixed 
effect model (The DerSimonian and Laird method). The Breslow-Day test was used to 
examine the statistical evidence of heterogeneity across the studies (p<0.1). Potential 
publication bias was examined by constructing a “funnel plot”, in which sample size was 
plotted against odds ratios. The study quality was evaluated by two investigators according 
to a score, modified from Jadad et al. (26) and Biondi-Zoccai et al. (27), that was expressed 
on a ordinal scale, allocating 1 point for the presence of each of the following: 1) statement 
of objectives; 2) explicit inclusion and exclusion criteria; 3) description of intervention; 4) 
objective means of follow-up; 5) description of adverse events; 6) power analysis; 7) 
description of statistical methods; 8) multicenter design; 9) discussion of withdrawals; 10) 
details on medical therapy (e.g. hydration or NAC) during and after the procedure. A 
prespecified analysis was conducted according to the dosage of statins (high-dose, 
rosuvastatin 40 mg or Atorvastatin 80 mg, and non-high dose). 
A meta-regression analysis was carried out to evaluate the relationship between benefits 
from statins and patient’s risk profile (as evaluated by the ODDS of CIN in the control 
group), the amount of contrast, cholesterol LDL, and the rate of diabetes. 
The study was performed in compliance with Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines (28). 
 RESULTS 
Eligible studies. Among 296 potentially relevant publications, 38 articles were considered 
of interest and reviewed in full text. Of these 30 studies were excluded because of 1) 
comparison between high vs with low-dose statins; 2) duplicate studies; 3) meta-analysis.  
Therefore a total of 8 trials (29-36) were finally included (Figure 1).  
 
Figure 1. Flow diagram of the systematic overview process. RCT = Randomized controlled trials. 
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Five (29-31, 33, 35) were single center randomized trials and three (32, 34, 36) were 
multicenter randomized trials, with a total of 4734 patients of which 2358 (49,8%) patients 
randomized to receive statin treatment pre-procedure and 2376 (50,2%) to placebo. Clinical 
characteristics of included trials are shown in Table 1 and Table 2.  
 
 Table 1. Characteristics of included studies. 
 
Table 2. Characteristics of included studies. 
 
 Five studies (29,31,33-35) used therapy with high-dose statins (Atorvastatin 80 mg or 
Rosuvastatin 40 mg) while three studies (30,32,36) used low-dose statin therapy 
(Rosuvastatin 10mg, Simvastatin 40mg or Atorvastatin 40mg). The total duration of statin 
treatment before angiography ranged from 12 hours to 3 days. CIN was defined differently 
among the included studies. Four studies (29-30,32,34) used an increase in serum creatinine 
of >0,5mg/dL or >25% from baseline within 48 hours after procedure, other three studies 
(31, 35,36) used the same definition within 72 hours and one study (33) regarded an 
absolute increase in serum creatinine of 0,5 mg/dL within 5 days after contrast exposure. 
Three studies (32, 33, 36) included patients with Creatinine clearance < 60ml/min, one 
study (29) enrolled patients with creatinine clearance < 70ml/min or Serum creatinine > 
1,5mg/dL, two studies (34, 35) excluded patients with serum creatinine > 3mg/dL and only 
one study (31) had no restrictions according to renal function. All studies enrolled patients 
undergoing coronary angiography or percutaneous interventions, focusing on STEMI 
patients in the study of Li et al (31), on NSTEMI-ACS patients in Patti at al. and in the 
PRATO-ACS trial (34-35) and in patients with diabetes and chronic kidney disease in the 
study by Han et al (36). All patients received low-osmolar or iso-osmolar contrast media 
and the mean contrast volume ranged from 93 to 213 ml. Peri-procedural hydration was 
administered in all patients except for the study of Patti et al. (34) in which hydration was 
administered only in patients with creatinine clearance < 60ml/min. Four studies (29, 31, 33, 
35) used also N-acetylcysteine in association with hydration.   
 
 
 
 Statins and Risk of CIN 
CIN was observed in 79 out of 2358 patients (3.3%) in the statin group versus 153 out of 
2376 patients (6.4%) in the placebo group (OR [95%CI] = 0.50 [0.38 - 0.66], p<0.0001; phe 
= 0.39) (Figure 2).  
 
Figure 2. Statin vs placebo and occurrence of CIN, with odds ratios and 95% confidence intervals 
(CI). The size of the data markers (squares) is approximately proportional to the statistical weight of 
each trial. 
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 Figure 3. Funnel plot of all studies included in the meta-analysis. The Standard Error (SE) of the 
log Odds Ratio of each study was plotted against the Odds Ratio for CIN. No skewed distribution 
was observed, suggesting no publication bias. 
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Benefits were both observed with high-dose short-term statin therapy (OR [95% CI] =0.44 
[0.30-0.65], p<0.0001; phet =0.16) and low-dose short-term statin therapy, 
(OR[95%CI]=0.58[0.39-0.88],p=0.01;phet=0.90). By meta-regression analysis we did not 
find a relationship between benefits from statins and patient’s risk profile (beta[95%CI] = -
0.53[-1.47 – 0.40],p = 0.26) (Figure 4) (Table 3), contrast agent volume (beta [95% CI] = 
0.0003 [-0.007 - 0.007], p = 0.94) (Figure 4) (Table 3), LDL-cholesterol (beta [95% CI] = -
0.007 [-0.02 – 0.01], p = 0.40) (Figure 4) (Table 3) and diabetes rate (beta [95% CI] = -0.050 
[-0.161 – 0.06], p = 0.38) (Figure 4) (Table 3). 
 
 
 
 Table 3. Meta-regression analysis evaluating the relationship between benefits from statins and 
patient’s risk profile, rate of diabetes, amount of contrast, ejection fraction and baseline cholesterol 
LDL.  
 
Figure 4. Meta-regression analyses shows no relationship between benefits from statins in 
prevention of CIN (as Log odds ratio) and patients risk profile (expressed as odds of CIN of control 
group) (A), baseline LDL cholesterol (B), diabetes rate (C), contrast medium dose (D) 
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 DISCUSSION 
The main finding of the study is that short-term statin therapy as compared to placebo, was 
associated with a significant reduction in the risk of CIN and benefits were observed with 
both high-dose statins and low-dose statins. In the last decades, although hydration has been 
well recognized in literature as the most effective strategy for the prevention of CIN, the 
total incidence of CIN did not decrease. This may be due to the higher complexity of 
patients currently undergoing percutaneous revascularization, as a consequence of the great 
improvement in antithrombotic therapies and mechanical devices, especially in the setting 
of acute coronary syndromes (37-40). Several other therapies, such as alkalinization 
measures (11-12), the use of scavengers such as N-acetylcysteine (NAC) (13), drugs as 
Fenoldopam, hemodyalisis and hemofiltration (14-16) were assessed for the prevention of 
CIN, leading to conflicting results. Therefore, the efficacy of many other prophylactic 
measures is still under testing. Statins, in addition to their impact on cholesterol levels have 
been shown to possess multiple non lipid-lowering pleiotropic effects such as anti-oxidant, 
anti-inflammatory and anti-thrombotic properties with enhancement of endothelial nitric 
oxide production and reducing of endothelin secretion (19-20). The role of statins for the 
prevention of CIN was assessed also in animal models in which statins prevent ischemic 
nephropathy by stabilizing the endothelium and acting as free radical scavengers (41-42).   
As well known from literature, the pathogenesis of CIN is the result of endothelial 
dysfunction, cellular toxicity from the contrast agent and tubular apoptosis resulting from 
hypoxic damage or reactive oxygen species (1), therefore, pharmacological prophylactic 
strategies based on antioxidant properties have been considered for its prevention. The anti-
inflammatory effect of statins inhibits tissue factor expression by macrophages, preventing 
 the activation of nuclear factor-kB and consequently reducing toxic damage on the tubular 
cells by pro-inflammatory cytokines and oxygen free radicals (43). Moreover, with the 
down-regulation of angiotensin receptors and the decreasing of endothelin-1, statin therapy 
may modulate kidney hypoperfusion due to contrast exposure (44). Due to these important 
properties, in the last decades a large number of studies have assessed the role of statins for 
the prevention of CIN in patients undergoing coronary angiography or percutaneous 
interventions, with conflicting results (21-25). The ARMYDA-CIN trial showed that a 
short-term, high dose Atorvastatin therapy prevents CIN and shortened hospital stay in 241 
patients with acute coronary syndrome undergoing PCI (34). On the other side Toso et al. 
(33), showed that short term administration of high dose Atorvastatin before and after 
contrast exposure did not decrease CIN occurrence in patients with pre-existing chronic 
kidney disease (11% of patients developed CIN in the placebo group versus 10% in the 
atorvastatin group, p=0.86). However, the same group showed that among ACS patients 
high-dose Rosuvastatin was associated with a significant reduction in the risk of CIN (35). 
The study of Han at al. (36) is at the moment the biggest study (including almost 3000 
patients with type 2 diabetes mellitus and chronic kidney disease) showing that low dose 
Rosuvastatin 48h pre and 72 h post coronary angiography or PCI significantly reduced the 
risk of CIN (p=0.02). 
The role of statins for the prevention of CIN has already been assessed in several previous 
meta-analysis, with contrasting results. In fact, Pappy et al. (45) and Zhang T et al. (46) 
showed a non significant reduction in the incidence of CIN with statin treatment from the 
pooled estimate from the randomized trials, whereas other recent meta-analysis are in line 
with our results (47-49) supporting the beneficial effects of statins in the prevention of CIN. 
 However, it must be underscored that all of them failed to include all currently available 
randomized trials (35-36), and some of them included both cohort studies or randomized 
trials (47-48) comparing high vs low dose statins (49). This is largest meta-analysis so far 
conducted, including 8 randomized trials with a total of 4734 patients. We found that short-
term statin therapy was associated with a significant reduction in risk of CIN in both trials 
with low and high-dose statins, even though some larger benefits were observed with higher 
doses. By meta-regression analysis we found that the benefits from statins were not affected 
by patients risk profile, contrast volume, rate of diabetes, LDL cholesterol or ejection 
fraction. These results, similar to those of other meta-analyses, encourage the use of statins 
for the prevention of contrast induced nephropathy, even in patients with LDL cholesterol 
below the recommended threshold. 
LIMITATIONS 
This meta-analysis was performed on limited individual patient data, as complete datasets 
were not available. Contrast induced nephropathy is a common complication that has shown 
to occur in up to 20-25% of patients depending on the presence of known risk factors, such 
as chronic renal insufficiency, diabetes mellitus and the dose of contrast medium. Therefore, 
access to individual patient data would have enabled further subgroup analyses. Studies 
included in this meta-analysis assessed the efficacy of different statins for varied periods of 
time and is possible that dose, duration and statin type may have different effects for the 
prevention of CIN. However, the included studies did not provide insights on the 
mechanisms that could explain the beneficial effects of statins in the prevention of CIN.  All 
studies used the traditional definition of contrast induced nephropathy (CIN, defined as 
increase of creatinine > 0.5 mg/dl or increase by 25% as compared to baseline), whereas a 
 new definition (CIAKI, contrast-Induced Acute Kidney Injury) has recently been proposed 
(50). Finally, even if all included studies reported the incidence of CIN no trial reported on 
long-term mortality or the progression of kidney failure at follow-up, which are clinically 
relevant outcomes due to the chronic progressive nature of this disease. 
 
CONCLUSIONS  
The present meta-analysis has demonstrated that among patients undergoing coronary 
angiography or percutaneous intervention the use of short-term statin reduces the incidence 
of CIN, and therefore are highly recommended to prevent such a complication, even in 
patients with LDL cholesterol below the recommended threshold. 
 
References 
1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428. 
2. James MT, Gali WA et al. Acute kidney injury following coronary angiography is associated with a long-term 
decline in kidney funcion. Kidney Int 2010; 78: 803-809 
3. Nash K, Hafeez A, Hou S e al. Hosputal acquired renal insufficiency Am J Kidney Dis 39:930-6. 
4. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428. 
5. Maeder M, Klein M, Fehr T et al. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 
2004; 44:1763-1771. 
6. De Luca G, Bellandi F, Huber K et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab 
long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 
2011; 9: 2361-70.  
7.  De Luca G, Cassetti E, Verdoia M et al. Bivalirudin as compared to unfractionated heparin among patients 
undergoing coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost 2009 
Sep;102(3):428-36.  
8. Di Lorenzo E, Sauro R, Varricchio A et al. Benefits of drug-eluting stents as compared to bare metal stent in 
ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs 
bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50. 
 9. Navarese EP, Kubica J, Castriota F et al. Safety and efficacy of biodegradable vs. durable polymer drug-
eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011; 7: 985-94. 
10. De Luca G, Dirksen MT, Spaulding C et al. Drug-Eluting Stent in Primary Angioplasty (DESERT) 
Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of 
randomized trials. Arch Intern Med 2012; 172: 611-21.  
11. Merten GJ Burgess WP, Gray LV et al. Prevention of Contrast-Induced Nephropathy with Sodium 
Bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334. 
12.  From AM, Bartholmai BJ, Williams AW et al. Sodium Bicarbonate is associated with an increased incidence 
of Conrast Nephropathy: A retrospective study. Clin J Am Soc Nephrol 2008;3:10-18 
13. Marenzi G, Assanelli E, Marana I et al. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary 
Angioplasty. NEJM 2006;354:2773-82 
14.  Stone GW, McCullough PA, Tumlin JA, et al. CONTRAST Investigators.  Fenoldopam mesylate for the 
prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290: 2284-2291  
15. Schindler R, Stahl C, Venz S et al. Removal of contrast media by different extracorporeal treatments. Nephrol 
Dial Transplant 2001; 16: 1471-1474  
16. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by 
hemofiltration. N Engl J Med 2003; 349:1333-1340   
17. Pannu N, Wiebe N, Tonelli M. Prophylaxis Strategies for Contrast-Induced Nephropathy. JAMA 
2006;295:2765-2779.  
18.  Barrett BJ, Parfrey PS. Preventing Nephropathy Induced by Contrast Medium NEJM 2006;354:379-86 
19. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in 
the primary prevention of acute coronary events N Engl J Med 344:1959-65. 
20. Zhang BC, Li WM, Xu YW et al. High-dose statin pre-treatment for the prevention of contrast induced 
nephropathy: a meta analysis. Can J Cardiol 2011;27:851-58. 
21. Khanal S, Attallah N, Smith DE et al. Statin therapy reduces contrast induced nephropathy : an analysis of 
contemporary percutaneous interventions Am J Med 2005;118:843-849. 
22. Attallah N, Yassine L, Musial J et al. The potential role of statins in contrast nephropathy Clin Nephrol 
2004 ;62 :273-278. 
23. Zhao JL, Yang YJ, Zhang YH et al. Effect of statins on contrast induced nephropathy in patients with acute 
myocardial infarction treated with primary angioplasty. Int J Cardiol 2008;126:435-436. 
24. Yoshida S, Kamihata H, Nakamura S et al. Prevention of contrast induced nephropathy by chronic pravastatin 
treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009;54:192-198. 
25. Kandula P, Shah R, Singh N et al. Statins for prevention of contrast induced nephropathy in patients 
undergoing non-emergent percutaneous coronary intervention. Nephrology 2010;15:165-170. 
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is 
blinding necessary? Control Clin Trials 1996; 17: 1–12. 
27. Biondi-Zoccai GG, Abbate A, Agostoni P, et al. Stenting versus surgical bypass grafting for coronary artery 
disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 2003; 4: 271–280. 
 28. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 
151: W65-94. 
29. Ozhan H, Erden I, Ordu S et al. Efficacy of Short-term High-Dose Atorvastatin for Prevention of Contrast-
Induced Nephropathy in patients undergoing Coronary Angiography. Angiology 2010; 61(7):711-4. 
30. Acikel S, Muderrisoglu H, Yldirir A et al. Prevention of contrast induced impairment of renal function by short 
term or long term statin therapy in patients undergoing elective coronary angiography. Blood Coagul 
Fibrinolysis 21(8):750-7. 
31. Li W, Fu W, Wang Y et al. Beneficial effects of high dose atorvastatin pretreatment on renal function in 
patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary 
intervention Cardiology 2012;122:195-202. 
32. Sang-Ho Jo, Bon-Know Koo, Jin-Shik Park et al. Prevention of radiocontrast medium induced nephropathy 
using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography 
(PROMISS) trial-a randomized controlled study. Am Heart J 2008;155:499.e1-499.e8. 
33. Toso A, Maioli M, Leoncini M et al. Usefulness of Atorvastitin (80mg) in prevention of contrast induced 
nephropathy in patients with chronic renal disease. Am J Cardiol 2010;105:288-292.  
34. Patti G, Ricottini E, Nusca A et al. Short term, high-dose Atorvastatin pre-treatment to prevent contrast 
induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary 
interventions (from the ARMYDA CIN trial) Am J Cardiol 2011;108:1-7. 
35. Leoncini M, Toso A, Maioli M et al. Early high-dose Rosuvastatin for contrast induced nephropathy 
prevention in acute coronary syndrome.J Am Coll Cardiol 2014;63:71-9. 
36. Han Y, Zhu G, Han L et al. Short term Rosuvastatin therapy for prevention of contrast induced acute kidney 
injury in patients with diabetesand chronic kidney disease. J Am Coll Cardiol 2014;63:62-70.  
37.  De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary 
angioplasty. Int J Cardiol 2013; 166: 606-12.  
38.  De Luca G, Navarese EP, Cassetti E et al. Meta-analysis of randomized trials of glycoprotein IIb/IIIa 
inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 2011; 
107: 198-203. 
39. Navarese EP, De Luca G, Castriota F et al. Low-molecular-weight heparins vs. unfractionated heparin in the 
setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J 
Thromb Haemost 2011; 9: 1902-15. 
40. Capozzolo C, Piscione F, De Luca G et al. Direct coronary stenting: effect on coronary blood flow, immediate 
and late clinical results. Catheter Cardiovasc Interv 2001; 53: 464-73. 
41. Gueler F, Rang S, Park JK et al. Post ischemic acute renal failure is reduced by short term statin treatment in a 
rat model J Am Soc Nephrol 2002;13:2288-98. 
42. Park JK, Muller DN, Mervala EM et al. Carivastatin prevents angiotensin II induced renal injury independent 
of blood pressure and cholesterol-lowering effects. Kidney Int 2000;58:1420-30. 
43. Bonetti PO, Lerman LO, Napoli C et al. Statin effects beyond lipid lowering: are they clinical relevant? Eur 
Heart J 2003;24:225-48. 
 44. Ichiki T, Takeda K, Tokunou T et al. Dowregulation of angiotensin II type 1 receptor by hydrophobic 3 –
hydroxy-3methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler 
Thromb Vasc Biol 2001;21:1896-901. 
45. Pappy R, Stavrakis S, Hennebry TA et al. Effect of statin therapy on contrast induced nephropathy after 
coronary angiography: A meta-analysis. Int J Cardiol 2011;15:348-53. 
46.  Zhang T, Shen LH, Hu LH et al. Statins for the prevention of contrast induced nephropathy: a systematic 
review and meta-analysis Am J Nephrol 2011;33:344-51. 
47. Zhou Y, Yuan WJ, Zhu N et al. Short term, high dose statins in the prevention of contrast induced 
nephropathy: a systematic review and meta-analysis. Clin Nephrol 2011;76:475-83. 
48. Zhang BC, Li WM, Xu YW et al. High-dose statin pretreatment for the prevention of contrast-induced 
nephropathy: a meta-analysis. Can J Cardiol. 2011 Nov-Dec;27(6):851-8.  
49. Li Y, Liu Y, Fu L et al. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a 
meta-analysis of seven randomized controlled trials. PLoS One. 2012;7(4):e34450.  
50. Lameire N, Kellum JA; for the KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and 
renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 2013; 17: 205 [Epub ahead of 
print]. 
 
 
 
 
 
 
 
 
 
 
 
 Part 4 
 
 
 
 
 
 
Impact of Trp719Arg polymorphism on 
patients undergoing coronary angiography 
or PCI 
 
 
 
 
 
 
 Chapter 8 
 
KIF 6 Polymorphism and coronary artery disease 
 
Methods 
Clinical, demographic and angiographic data of consecutive patients undergoing coronary 
angiography and/or PCI were collected in our dedicated database protected by password. 
Patients with impaired renal function at baseline (creatinine clearance <60ml/min) were 
treated with standard hydration (1ml/kg/h of saline solution 0.9% 12h before and after the 
procedure or with saline solution 0,5ml/kg/h, if ejection fraction ≤40% or with sodium 
bicarbonate received 3 ml/kg for 1h before contrast exposure followed by an infusion of 1 
ml/kg/h for 6h after the procedure). The association between KIF 6 variant and the extent of 
CAD was assessed after the coronary angiography by quantitative coronary angiography 
(QCA) analysis with “edge-detection system” (Siemens Acom Quantor QCA, Erlangen, 
Germany) by two experienced cardiologist who have not information about the patients’ 
genetic profile.  
 
Genetic analysis  
 
A blood sample for the determination of Trp719Arg polymorphism was collected for all 
patients. We therefore performed DNA extraction by the use of Sigma Aldrick Gen Elute 
system for each patient. We set the polymerase chain reaction (PCR) with reagents 
concentration optimization and MgCl2 concentration curve. Amplification of the region of 
interest with PCR and consequent electrophorethic run on agarose gel and digestion with 
restriction enzyme Fok I was performed for each sample. Digestion product underwent 
another electrophorethic run on agarose gel and subsequent analysis with UV scan. We 
therefore were able to identify the different allelic patterns of our population.  
 
 Coronary angiography and QCA 
 
Coronary angiography will be performed, preferring a radial approach, using 6-French right 
and left heart catheters. Quantitative coronary angiography will be performed by 
experienced interventional cardiologists by automatic edge-detection systems (Siemens 
Acom Quantcor QCA, Erlangen, Germany). After the visual inspection of the coronary 
artery, the frame of optimal clarity will be selected, showing lesion at maximal narrowing 
and arterial silhouette in sharpest focus. After the calibration of guiding catheter, analysed 
arterial segment with coronary lesion will be defined by moving the cursor from the 
proximal to the distal part of coronary artery to ensure adequate determination of reference 
diameter. We will measure minimal luminal diameter, reference diameter, percent diameter 
stenosis, and length of the lesion. Significant coronary artery disease will be defined as a 
stenosis more than 70%, while borderline stenosis if between 30 and 70%. 
 
Table 1. Clinical and demographic characteristics of patients according to KIF 6 polymorphism 
Variable KIF 6 polymorphism  
 
Clinical characteristics 
Trp-Trp 
(n = 486) 
Arg carriers 
 (n = 577) 
p-value 
Age (M-SD) 68.2+/-11.0 67.8+/-11.4 0.57 
Male sex (%) 66.3 68.5 0.47 
BMI (M-SD) 27.2+/-4.6 26.9+/-4.8 0.42 
Hypertension (%) 74.6 71.8 0.29 
Smokers (%)   
0.03 Active smokers (%) 21.5 21.5 
Previous smokers (%) 20.9 26.3 
Hypercolesterolemia (%) 54.6 56.3 0.62 
Diabetes (%) 35.3 36.9 0.61 
Previous AMI (%) 23.3 23.6 0.94 
Previous PCI (%) 17.5 19.8 0.38 
Previous CABG (%) 10.1 11.3 0.55 
Previous CVA (%) 6.0 7.1 0.46 
Renal failure (%) 23.2 24.4 0.66 
Ejection fraction (M-SD) 49.9+/-13.1 49.2+/-12.7 0.88 
Indication for angiography   
0.61 Stable angina or silent ischemia (%) 18.6 15.7 
Acute Coronary Syndrome (%) 63 66.9 
DCM or valvular disease (%) 18.4 17.4 
Baseline Chemistry    
White blood cells (M-SD) 8.1+/-2.9 7.9+/-2.7 0.23 
 Haemoglobin (M-SD) 13.4+/-1.6 13.3+/-1.7 0.14 
Platelet (M-SD) 216.4+/-62.2 222.7+/-71 0.13 
Glycaemia at admission (M-SD) 125+/-49.5 124.4+/-52 0.86 
Baseline creatinine (M-SD) 1+/-0.31 1.02+/-0.39 0.23 
Total Cholesterol (M-SD) 165.2+/-40.6 164.5+/-43.6 0.78 
HDL-Cholesterol (M-SD) 41.6+/-12.2 41.2+/-12.6 0.57 
Triglycerides (M-SD) 132.9+/-70.3 135+/-72.3 0.62 
LDL-Cholesterol (M-SD) 96.7+/-34.3 95.6+/-36.1 0.60 
Uric acid (M-SD) 6.2+/-1.8 6.1+/-1.8 0.41 
Reactive protein C (M-SD) 1.4+/-3.0 1.4+/-2.3 0.97 
Fibrinogen (M-SD) 439.3+/-133.9 438.2+/-134.6 0.89 
Homocysteine (M-SD) 17.7+/-8.2 18.4+/-9.0 0.22 
Theraphy at admission    
ACE I (%) 35.5 39.8 0.16 
ARB (%) 23.1 18.6 0.08 
Statins (%) 43.4 45.6 0.49 
Nitrate (%) 28.1 31.7 0.22 
Beta-Blockers (%) 47.7 47.7 1 
ASA (%) 50.8 56.7 0.06 
Clopidogrel (%) 15.5 20.3 0.04 
Calcium Antagonist (%) 19.4 21.4 0.44 
Diuretics (%) 29.5 29.9 0.95 
 
 
Table 2. Angiographic characteristics of patients according to KIF 6 polymorphism 
Variable KIF 6 polymorphism  
 
Procedural characteristics 
Absence 
(n = 486) 
Presence 
 (n = 577) 
p-value 
CAD detection (%) 80 80.7 0.81 
Multivessel disease (%) 80.1 81.6 0.22 
Left main - trivessel disease (%) 30.6 29.3 0.68 
Left main (%) 10.4 9.6 0.37 
Left anterior descending (%) 55.6 58.8 0.31 
Left circumflex (%) 44.3 46.1 0.57 
Right coronary artery (%) 50.0 51.0 0.75 
Type C lesion (%) 33.7 32.4 0.53 
Calcification (%) 18.4 22.7 0.02 
Thrombus (%) 5.8 4.8 0.36 
TIMI flow (%)  
 
0.32 
TIMI flow 0 22.1 21.3 
TIMI flow 1 3.3 2.3 
TIMI flow 2 4.6 3.7 
TIMI flow 3 69.9 72.7 
Restenosis (%) 2.7 3.4 0.43 
 Cronic total occlusion (%) 15.8 17.7 0.28 
Bifurcation (%) 20.8 22.2 0.44 
Dissection (%) 0.1 0.4 0.38 
Lesion lenght (M-SD) 20.3+/-12.9 20.3+/-12.1 0.93 
Stenosis percentage (M-SD) 87.6+/-14.1 86.5+/-13.7 0.08 
Reference diameter (M-SD) 2.97+/-0.63 2.95+/-0.61 0.37 
 
 
Results 
We analysed a total of 1063 patients undergoing coronary angiography and/or angioplasty. 
The polymorphic Arg variant of KIF 6 was found in 577 patients (heterozygotes n = 449, 
Homozygotes n = 128). Our population respect Hardy-Weinberg equilibrium (p = 0.118).  
Patients were divided in two groups according to the presence of  KIF 6 polymorphism 
(Group1, Trp-Trp n = 486; Group2, Arg carriers n = 577). Group 2 includes homo and 
heterozygous mutation. Patient’s baseline clinical and demographic characteristics, 
indication for angiography, baseline chemistry and admission therapy, according to  KIF 6 
polymorphism are listed in Table 1. Main angiographic characteristics are listed in Table 2. 
The two groups were quite homogeneous, with only a higher prevalence of previous 
smokers (26.3% vs 20.9%, p = 0.03) and chronic therapy with clopidogrel at admission 
(20.3% vs 15.5%, p = 0.04) in Group 2. About angiographic characteristics, patients of 
Group 2 showed a higher prevalence of calcific plaques at coronary angiography (22.7% vs 
18.4%, p = 0.02). The total prevalence of CAD in our population was 80.4% and we did not 
find any significant correlation between CAD and KIF 6 polymorphism (Group 1 80%, 
Group 2 80.7%, p = 0.81) (Figure 1).  
 
 
  
 
This result was confirmed by multivariate analysis after correction for baseline confounding 
factors (Adjusted OR [95%CI] = 0.98 [0.72-1.33], p=0.90). Similar results were also found 
dividing our population in three groups according to the genetic specific profile (Group 1, 
Trp homozygotes, n = 481; Group 2, heterozygotes, n = 449; Group 3, Arg homozygotes, n 
= 128) (Group 1 80%, Group 2 80.4%, Group 3 81.6%, p = 0.72). No significant differences 
between KIF 6 polymorphism and CAD detection were found also at subgroups analysis 
(Figure 2A) according to main risk factors for CAD such as diabetes (p int 0.46), renal 
failure (p int 0.13), statin therapy at admission (p int 0.71) and gender (p int 0.81), while the 
prevalence of CAD was higher in elderly patients carrying the Arg allele (87.1% vs 77.3%, 
p = 0.02 (p int 0.006). Absence of any interaction for main risk factors was observed for 
severe CAD (LM/trivessel disease) (Figure 2B). 
 
  
 
 
 
 Discussion and conclusion 
Our analysis shows the absence of correlation between Trp719Arg polymorphism of KIF 6 
and CAD in patients undergoing coronary angiography or PCI. Coronary artery disease 
(CAD) still represents the leading cause of death in developed countries (1,2). The 
improvement in pharmacological therapies and percutaneous revascularization procedures 
have greatly contributed to the relevant reduction in mortality observed in the last decades 
for coronary artery disease, particularly in the setting of acute myocardial infarction (3-5), 
however, the results are still unsatisfactory, especially in high-risk subgroups of patients. 
Therefore, large interests have been focused on the identification of new risk factors for 
CAD and its prevention. Statin therapy plays a central role in the setting of cardiovascular 
prevention and is also highly recommended both as chronic therapy in patients with CAD 
and with a loading dose in the early phase of acute coronary syndrome.  Genetics plays an 
important role in determining the inherent CAD vulnerability and in determining how a 
person responds to statin therapy.  The correlation between KIF 6 gene and an increased 
cardiovascular risk has been investigated since 2007 with prospective trials and meta-
analysis (6-8). Anyway these results were not confirmed in the large population of the Heart 
Protection study that involved more than 18000 patients (9). Our study was in line with 
these findings, showing the absence of association between KIF 6 polymorphism and the 
detection of CAD at coronary angiography. Moreover, similar results were observed in our 
population also regarding the detection of severe CAD, such as the presence of LM/trivessel 
disease. Interestingly, we found a higher prevalence of plaque calcifications among 
polymorphic patients that could explain the presence of more complex atherosclerotic 
disease, without a significant increase in the percentage of lesions’ severity (??) at 
 angiography. Several clinical trials (10,11) in last decades showed a significant association 
between anti-inflammatory, metabolics and vasoprotective effects of statin therapy and a 
reduction in cardiovascular events in the population with the risk allele. In our population 
we found a higher percentage of CAD among elderly patients carrying the Arg allele. 
Indeed the lower statin administration due to the lower adherence to preventive measures, 
polypharmacy and collateral effects could explain these results. In fact the percentage of 
severe CAD was lower (LM/trivessel disease) in Arg carriers with statin therapy at 
admission, suggesting a positive interaction between this genetic variant and statin therapy, 
although not reaching a statistically significant result. Probably, the routine use of more 
accurate imaging techniques, such as intravascular ultrasound (IVUS) or optical coherence 
tomography (OCT) would help us to better characterise coronary disease among the two 
groups of patients and to have more accurate results. Finally, an important limitation of our 
study is the absence of data about long term follow up. In future analysis we hope to be able 
to collect data at long term follow up in order to define the prognostic role of this genetic 
variant and to define any potential impact on the progression of CAD. In fact, we observed a 
larger prevalence of coronary calcifications, that are well-established early markers of the 
atherosclerotic process, in carriers of the Arg-variant and moreover, we reported a positive 
interaction of KIF-6 genetic status with age, suggesting potentially that a more prolonged 
exposure to the effects of  KIF-6 Arg-allele could favor the development of CAD. 
In conclusion our study showed absence of correlation between Trp719Arg polymorphism 
of KIF 6 and CAD in patients undergoing coronary angiography or PCI. However, a 
significant interaction was observed with age, being this polymorphism associated with an 
 increased risk of CAD only among elderly patients. Future large trials are certainly needed 
to further confirm our findings.  
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 Chapter 9 
 
KIF 6 Polymorphism and contrast induced nephropathy 
 
Methods 
Clinical, demographic and procedural data of consecutive patients undergoing coronary 
angiography and/or PCI were collected in our dedicated database protected by password. 
Patients with impaired renal function at baseline (creatinine clearance <60ml/min) were 
treated with standard hydration (1ml/kg/h of saline solution 0.9% 12h before and after the 
procedure or with saline solution 0,5ml/kg/h, if ejection fraction ≤40% or with sodium 
bicarbonate received 3 ml/kg for 1h before contrast exposure followed by an infusion of 1 
ml/kg/h for 6h after the procedure). Serum creatinine and creatinine clearance (calculated by 
applying Cockroft Gault formula) were collected at baseline, 24 and 48 hours after contrast 
exposure.  Among these patients we assessed the incidence of CIN, defined as an absolute 
increase of 0.5mg/dL or a relative increase >25% in serum creatinine levels at 24 and 48h 
after the procedure. 
 
Genetic analysis  
 
A blood sample for the determination of Trp719Arg polymorphism was collected for all 
patients. We therefore performed DNA extraction by the use of Sigma Aldrick Gen Elute 
system for each patient. We set the polymerase chain reaction (PCR) with reagents 
concentration optimization and MgCl2 concentration curve. Amplification of the region of 
interest with PCR and consequent electrophorethic run on agarose gel and digestion with 
restriction enzyme Fok I was performed for each sample. Digestion product underwent 
another electrophorethic run on agarose gel and subsequent analysis with UV scan. We 
therefore were able to identify the different allelic patterns of our population.  
 
 Table 1. Clinical and procedural characteristics of patients according to KIF 6 polymorphism 
Variable KIF 6 polymorphism  
 
Clinical characteristics 
Trp-Trp 
(n = 584) 
Trp-Arg 
(n = 525) 
Arg-Arg 
 (n = 144) 
p-value 
Age (M-SD) 68.1+/-10.7 67.8+/-11 68+/-12.3 0.90 
Male sex (%) 68.2 71.6 65.3 0.94 
Hypertension (%) 75.9 72.2 80.6 0.81 
Smokers (%)    
0.26 Active smokers (%) 19.9 20.6 22.9 
Previous smokers (%) 22.1 28.4 20.1 
Hypercolesterolemia (%) 58 56.2 66 0.31 
Diabetes (%) 35.3 35.4 42.4 0.23 
Family history of CAD (%) 26.6 27.4 33.3 0.17 
Previous AMI (%) 27.2 24.8 27.1 0.66 
Previous PCI (%) 26 28.2 28.5 0.40 
Previous CABG (%) 10.9 12.8 12.5 0.40 
Previous CVA (%) 6.8 6.9 6.3 0.85 
Renal failure (%) 12.8 15.8 15.3 0.21 
Indication for angiography    
 
0.15 
Stable angina or silent ischemia (%) 22.2 22.3 20.2 
Acute Coronary Syndrome (%) 55.9 59.9 67.7 
DCM or valvular disease (%) 22 17.8 12.1 
Baseline Chemistry     
Haemoglobin (M-SD) 13.5+/-1.6 13.3+/-1.7 12.9+/-1.6 0.03 
Platelet (M-SD) 214.4+/-60.3 219.4+/-70.5 225.1+/-70.5 0.16 
Glycaemia at admission (M-SD) 127+/-48.4 124.6+/-47.2 125.3+/-64.7 0.07 
Baseline creatinine (M-SD) 1+/-0.28 1.05+/-0.45 1.01+/-0.36 0.08 
Absolute creatinine increase (M-SD) 0.08+/-0.27 0.07+/-0.24 0.11+/-0.31 0.30 
Relative creatinine increase (M-SD) 0.09+/-0.26 0.09+/-0.19 0.13+/-0.31 0.20 
Creatinine clearance (M-SD) 78.8+/-31.6 78+/-34.6 79.7+/-34.2 0.83 
Reactive protein C (M-SD) 1.34+/-3.02 1.33+/-2.43 1.36+/-2.46 0.99 
Total Cholesterol (M-SD) 160.6+/-40.8 161.5+/-43.1 158.1+/-44.7 0.70 
HDL-Cholesterol (M-SD) 41.6+/-13.4 41.2+/-13 41.5+/-13.9 0.84 
Triglycerides (M-SD) 134+/-71.2 139.4+/-98.8 132.6+/-67.9 0.48 
LDL-Cholesterol (M-SD) 93.3+/-36.3 93.6+/-39.9 90.8+/-38.7 0.74 
Procedural characteristics     
PTCA (%) 58.6 61.3 55.2 0.89 
Radial access (%) 33.2 36.2 36.1 0.32 
Contrast volume (M-SD) 233.7+/-157 231.3+/-152.5 237.4+/-172.9 0.91 
Theraphy at admission     
ACE I (%) 41.4 42.3 43.4 0.76 
ARB (%) 26.9 20.2 19.2 0.01 
Statins (%) 54.3 50.9 58.3 0.90 
Nitrate (%) 35.8 39.2 36 0.58 
Beta-Blockers (%) 57.7 57 46 0.04 
ASA (%) 59.6 61.7 71.1 0.03 
Clopidogrel (%) 20.8 26.4 29.3 0.01 
 Calcium Antagonist (%) 22.2 21.9 27.5 0.35 
Diuretics (%) 35.2 32.1 36.8 0.82 
 
Results 
We analysed a total of 1253 patients undergoing coronary angiography and/or angioplasty. 
KIF 6 Arg mutation was found in 669 patients (heterozygotes n = 525, homozygotes n = 
144). Our population respect Hardy-Weinberg equilibrium (p = 0.14). Patient’s baseline 
clinical and demographic characteristics, indication for angiography, procedural 
characteristics, baseline chemistry and admission therapy, according to the presence of  KIF 
6 polymorphism are listed in Table 1. Patients without polymorphism were more often in 
therapy with angiotensin receptor blockers (ARB) (p = 0.01), beta blockers (p = 0.04), but 
less with acetylsalicylic acid (ASA) (p = 0.03) and clopidogrel (p = 0.01) at admission and 
they have higher haemoglobin levels at admission (p = 0.03). No other significant 
differences were found between the three population. The total prevalence of CIN in our 
population was 12.5% and we did not find any significant association between KIF 6 
polymorphism and the development of CIN (Group 1 11.3%, Group 2 13.7%, Group 3 
13.2% p = 0.30) (Figure 1). This result was confirmed by multivariate analysis after 
correction for baseline confounding factors (Adjusted OR [95%CI] = 1.12 [0.86-1.46], 
p=0.38). 
  
 
Similar results were found dividing our population in two groups according to the genetic 
status (Group 1 11%, Group 2 13.7%, p = 0.19). At subgroups analysis we found a higher 
prevalence of CIN among homozygous patients treatment “naïve” in comparison to wild-
type patients (20.7% vs 11.3%, p = 0.05), while patients with statin therapy at admission 
showed a lower CIN development without reaching a statistical significant result (8.6% vs 
13.2%, p = 0.28) (p int 0.03). No other significant differences between homozygous KIF 6 
polymorphism and CIN development according to main risk factors for CIN such as 
diabetes (p int 0.49), renal failure (p int 0.50), gender (p int 0.25), older age (p int 0.67) and 
PCI (p int 0.92). (Figure 2).  
 
  
 
 
Discussion and conclusion 
The main finding of our study is the presence of a significant correlation between statin 
therapy modulation among KIF 6 homozygous Arg patients and the development of CIN 
after coronary angiography or percutaneous intervention.  
Several clinical trials and meta analysis (1-4) showed a significant association between anti-
inflammatory, metabolics and vasoprotective effects of statin therapy and a reduction in 
cardiovascular events in the population with the risk allele. Recent studies (5,6) showed a 
protective effect of statin therapy in patients treated before coronary angiography/PCI. 
Statins, in addition to their impact on cholesterol levels have been shown to possess 
 multiple non lipid-lowering pleiotropic effects such as anti-oxidant, anti-inflammatory and 
anti-thrombotic properties with enhancement of endothelial nitric oxide production and 
reducing of endothelin secretion (7,8). As well known from literature, the pathogenesis of 
CIN is the result of endothelial dysfunction, cellular toxicity from the contrast agent and 
tubular apoptosis resulting from hypoxic damage or reactive oxygen species (9), therefore, 
pharmacological prophylactic strategies based on antioxidant properties have been 
considered for its prevention. In our population we found that statin therapy at admission 
did not influence the development of CIN in overall population, while, there was a 
significant interaction between CIN development,  Arg homozygote carriage and  statins, 
suggesting that the nefro-protective effects of these drugs could be even more relevant in 
carriers of the KIF-6 variant allele. In fact, Arg homozygotes not treated with statins at the 
moment of angiography were at enhanced risk of CIN. These results give great effort for a 
systematic and early use of statin therapy in patients undergoing coronary angiography or 
percutaneous coronary intervention. One of the limitation of our study was that we 
evaluated the occurrence of CIN at 48-72 hours, but this complication may appear even later 
than this time threshold. Furthermore, we were not able to provide data on the progression 
of kidney failure at follow-up, being this disease chronically progressive. Future large 
studies are certainly needed to confirm our finding, in order to confirm benefits of statin 
treatment on the development of CIN. 
In conclusion our study showed among patients undergoing coronary angiography and/or 
PCI that KIF 6 homozygous Arg was associated with a significant increase in the risk of 
CIN only among statin naive patients. Future additional studies are certainly needed to 
 confirm our findings and to evaluate the beneficial effects of statin therapy especially in this 
subset of patients.   
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 Chapter 10 
 
KIF 6 and the modulation of the protective effects of statin in naïve 
patients 
 
Methods 
Clinical, demographic and procedural data of consecutive patients undergoing coronary 
angiography and/or PCI, treatment naïve for statin, were collected in our dedicated database 
protected by password. Patients with impaired renal function at baseline (creatinine 
clearance <60ml/min) were treated with standard hydration (1ml/kg/h of saline solution 
0.9% 12h before and after the procedure or with saline solution 0,5ml/kg/h, if ejection 
fraction ≤40% or with sodium bicarbonate received 3 ml/kg for 1h before contrast exposure 
followed by an infusion of 1 ml/kg/h for 6h after the procedure). For each patient chemistry 
including total, HDL and LDL cholesterol were assessed at baseline. Each patient received 
statin treatment at admission according to good clinical practice. Chemistry including total, 
HDL and LDL cholesterol were then assessed at time 1 (at least 30 days after discharge).  
 
Genetic analysis  
 
A blood sample for the determination of Trp719Arg polymorphism was collected for all 
patients. We therefore performed DNA extraction by the use of Sigma Aldrick Gen Elute 
system for each patient. We set the polymerase chain reaction (PCR) with reagents 
concentration optimization and MgCl2 concentration curve. Amplification of the region of 
interest with PCR and consequent electrophorethic run on agarose gel and digestion with 
restriction enzyme Fok I was performed for each sample. Digestion product underwent 
another electrophorethic run on agarose gel and subsequent analysis with UV scan. We 
therefore were able to identify the different allelic patterns of our population.  
 Results 
We analysed a total of 109 patients undergoing coronary angiography and/or angioplasty 
statin treatment naive. Arg-carriers were 59 patients, while 49 patients displayed wild-type 
genotype. Patients were divided in two groups according to the presence of KIF 6 
polymorphism (Group1, Trp-Trp patients n = 49; Group 2, Arg-carriers n = 60). Group 2 
includes homo and heterozygous mutation. Patient’s baseline clinical and demographic 
characteristics, indication for angiography, baseline chemistry and admission therapy, 
according to the presence of  KIF 6 polymorphism are listed in Table 1. 
 
Table 1. Clinical and demographic characteristics of patients according to KIF 6 polymorphism 
Variable KIF 6 polymorphism  
 
Clinical characteristics 
Trp-Trp 
(n = 49) 
Arg carriers 
 (n = 60) 
p-value 
Age>75 (%) 14.3 36.7 0.009 
Age (M-SD) 64.3+/-10.8 66.4+/-12.8 0.37 
Male sex (%) 76.8 74.5 0.77 
BMI (M-SD) 27.3+/-3.9 26.2+/-3.9 0.17 
Hypertension (%) 73.5 55 0.07 
Smokers (%)   
0.32 Active smokers (%) 20.4 38.3 
Previous smokers (%) 18.4 16.7 
Hypercolesterolemia (%) 42.9 56.7 0.18 
Diabetes (%) 40.8 28.3 0.22 
Previous AMI (%) 8.2 11.7 0.75 
Previous PCI (%) 30.6 15 0.06 
Previous CABG (%) 0 5 0.25 
Renal failure (%) 6.1 18.3 0.08 
Ejection fraction (M-SD) 52+/-10.1 52.2+/-9.5 0.93 
Baseline Chemistry    
White blood cells (M-SD) 7.8+/-2.1 7.9+/-1.9 0.68 
Haemoglobin (M-SD) 13.7+/-1.6 13.1+/-1.9 0.10 
Platelet (M-SD) 235.4+/-70 242+/-86.6 0.67 
Glycaemia at admission (M-SD) 122.6+/-36 110.8+/-27.6 0.05 
Glycated haemoglobin (M-SD) 6.4+/-1.1 6.2+/-0.87 0.20 
Baseline creatinine (M-SD) 0.89+/-0.15 1.04+/-0.84 0.22 
Total Cholesterol (M-SD) 187.3+/-39.5 184.6+/-45.4 0.75 
HDL-Cholesterol (M-SD) 43.8+/-11 42.3+/-12.2 0.44 
 Triglycerides (M-SD) 108.6+/-58.6 112+/-62.1 0.77 
LDL-Cholesterol (M-SD) 116.7+/-35.4 118.6+/-39 0.80 
Reactive protein C (M-SD) 0.71+/-0.94 0.49+/-0.81 0.44 
Theraphy at admission    
ACE I (%) 63.3 58.3 0.69 
ARB (%) 24.5 15 0.23 
Nitrate (%) 46.9 38.3 0.43 
Beta-Blockers (%) 93.9 90 0.51 
ASA (%) 98 98.3 0.99 
Clopidogrel (%) 62.5 90 0.10 
Calcium Antagonist (%) 18.4 13.3 0.59 
Diuretics (%) 24.5 23.3 0.99 
 
Arg carriers were more often older than 75 years old (36.7 vs 14.3, p = 0.009) and have 
lower glycaemia level at admission (110.8+/-27.6 vs 122.6+/-36). No other significant 
differences were found in any other biochemical parameter or clinical characteristic between 
the two population. All patients at admission received statin treatment. The median time 
from baseline to re-assessment was 86 days [IQR 45-236]. As expected, at the established 
follow up we found a significant reduction in total cholesterol (132.6 vs 185.4, p < 0.001) 
and LDL cholesterol (68.9 vs 117.8, p < 0.001) (Figure 1).  
  
KIF 6 polymorphism did not significantly influence both the absolute reduction of LDL 
(Group1, -51.7+/-38.8  vs Group2 -50.1+/-42.2, p = 0.83) and the relative reduction of LDL 
cholesterol (Group1, -39.9%+/-24.4% vs Group2 -37.3%+/-25.7%, p = 0.60). A total of 71 
patients received high intensity statin therapy (Atorvastatin > 40mg, Rosuvastatin > 20mg). 
Among these patients 35 were wild-type and 36 Arg carriers. KIF 6 polymorphism did not 
affect the absolute (Group1, -56.3+/-43.3 vs Group2 -59.2+/-42.8, p = 0.78) and relative 
LDL (Group1, -41.%+/-27% vs Group2 -43.3%+/-21.5%, p = 0.69) decrease of LDL 
cholesterol also when considering the group receiving high intensity statin treatment (Figure 
2). 
  
 
Discussion and conclusion 
The main finding of our study is the absence of a correlation between KIF 6 polymorphism 
and LDL reduction at follow up among statin naïve patients. Statin treatment played a 
central role in the setting of cardiovascular prevention, in fact, in addition to their impact on 
cholesterol levels, statins have been shown to possess multiple non lipid-lowering 
pleiotropic effects such as anti-oxidant, anti-inflammatory and anti-thrombotic properties 
with enhancement of endothelial nitric oxide production and reducing of endothelin 
secretion (1-3). Therefore they are highly recommended both as chronic therapy in patients 
with CAD, but also with a loading dose in the early phase of acute coronary syndrome to 
 stabilize the plaque and reduce the incidence of any complication, especially if a 
percutaneous coronary intervention (PCI) is performed. Genetics plays an important role in 
determining the inherent CAD vulnerability and in determining how a person responds to 
statin therapy. Kinesis-Like Protein 6 (KIF 6) is an omodimeric protein expressed in 
coronary arteries and other vascular tissues, that is involved in cellular microtubular 
transport (14).The impact of KIF 6 gene on cardiovascular risk modulation has been 
investigated in several prospective trials and meta-analysis (4-6) assessed the association 
between this genetic variant and a significant increase of cardiovascular risk. Particular 
attention in last years has been focused on the role of the Trp719ARg polymorphism in the 
modulation of response to statin treatment. Several clinical trials showed a significant 
association between anti-inflammatory, metabolic and vasoprotective effects of statin 
therapy and a reduction in cardiovascular events in the population with the risk allele (7,8). 
Moreover these protective effects with a significant reduction (about 13%) of LDL-
cholesterol level and risk of cardiovascular events of statin therapy has been recently 
confirmed by two meta-analysis (9,10). Our population was represented by consecutive 
patients, statin treatment naïve, undergoing coronary angiography/PCI. We found that the 
genetic variant did not significantly influence the response to statins, defined as the 
reduction in LDL cholesterol. Results were similar when restricting the analysis to high 
intensity statin treatment. Indeed, these results could be explained both by the small size of 
our sample and the use of high intensity statins in the majority of the population, that could 
have potentially overcame the effect of the polymorphism. Nevertheless, cholesterol 
reduction does not represent the only mechanism by which the statins can reduce the 
cardiovascular risk. Therefore, it might be argued that the positive interaction between statin 
 administration and KIF-6 polymorphism documented in previous trials could have been 
dependent by those “pleiotropic”, non-lipid dependent effects of statins.  
Indeed, we did not consider other inflammatory biomarkers or their transient changes after 
statin administration, according to KIF 6 genetic status, in our patients. Nevertheless, no 
study has so far addressed the pathophysiological basis of statin-KIF 6 interplay, and in 
addition, the anti-atherosclerotic effects of statins include a broad spectrum of actions, not 
yet completely defined. Therefore, future larger studies on will help us to better define the 
correlation between KIF 6 polymorphism and the effects of statins. 
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 Summary and conclusions 
 
Coronary artery disease  is the leading cause of mortality in western countries. Therefore 
large efforts have been done in the last decades to identify new risk factors and new 
preventive strategies, with a special look at the interaction between the genetic background 
and environmental factors. In particular, several biomarkers involved in the inflammatory 
processes and in the development of the atherosclerotic plaque have been addressed, 
although with inconclusive results. Genetics determinants of cardiovascular risk have 
recently emerged as an additional tool for the stratification and prognostic evaluation of 
patients with cardiovascular disease. The present thesis provides a focus on  several 
molecular aspects of the diagnosis and treatment of CAD and its complications, including 
contrast-induced nephropathy. In Part 2 we focused on cardiovascular risk assessment and 
evaluation of coronary artery disease as evaluated by coronary angiography. In Chapter 2, 
we found that that uric acid levels are significantly higher in men; however, high uric acid 
levels are associated with severe CAD only in women. In Chapter 3 we found a significant 
independent association between NLR and the prevalence and severity of CAD. The 
extensive treatment of coronary artery disease by percutaneous coronary intervention and 
the high-risk profile of patients currently undergoing angiography or PCI, has driven  a lot 
of interests on the occurrence of contrast-induced nephropathy (CIN), that is a common 
complication of procedures that foresee the use of contrast media and is known as the third 
leading cause of hospital-acquired acute kidney injury. Great efforts have been done to 
identify new risk factors that foresee this complication and potential preventive strategies, 
that is the aim of Part 3. In Chapter 4, we showed that among patients without diabetes 
 undergoing coronary angiography/PCI elevated glycated-haemoglobin but not glucose 
levels is independently associated with the risk of CIN. In Chapter 5 and 6 we specially 
focused on Homocysteine and Uric acid, and found both of them independently associated 
with the occurrence of CIN. In Chapter 7, by the use of a meta-analysis approach, we 
showed that among patients undergoing coronary angiography/percutaneous intervention 
the use of short-term statin reduces the incidence of CIN. 
We finally focused in Part 4 on the genetics and in particular on the KIF-6 719 Trp>Arg 
polymorphism, evaluating its impact on CAD, CIN and the interplay with statin therapy. In 
Chapter 8, we did not find a significant association between KIF 6 polymorphism and CAD 
detection at coronary angiography. We found a higher prevalence of calcified plaques 
among polymorphic patients carrying the Arg mutation. In addition, in our population we 
found a higher percentage of CAD among elderly patients carrying the Arg allele, that could 
have been explained by the more prolonged exposure of these patients to the KIF-6 
mutation but also to statin under prescription, which is more common in advanced age.  
In Chapter 9, we evaluated the impact of KIF6 polymorphism and contrast induced 
nephropathy. We found that statin therapy at admission did not influence the development 
of CIN, while, there was a significant interaction between CIN development, homozygous 
Arg allele carriage and statin therapy. In fact, Arg homozygotes not treated with statins at 
the moment of angiography have an increased risk of CIN, suggesting that the nephro-
protective effects of these drugs could be even more relevant in carriers of the KIF-6 variant 
allele.  
 However, in Chapter 10 among naïve statin treatment patients we found that the genetic 
variant of KIF 6 did not significantly influence the reduction in LDL cholesterol at follow 
up, also in case of high intensity statin treatment administered. Therefore, it could be argued 
that the positive interaction between the cardioprotective effects of statins  and Arg-allele of 
KIF 6, documented in previous studies and in our Chapter 9, in particular on the risk of 
CIN, could be mediated by those pleiotropic non “cholesterol” dependent effects of statins.  
Indeed, the present study represents only an exploratory study on the topic, since no study 
has so far addressed the pathophysiological basis of statin-KIF 6 interplay, and in addition, 
the anti-atherosclerotic effects of statins include a broad spectrum of actions, not yet 
completely defined. Therefore, future large studies are certainly needed to better define the 
correlation between KIF 6 polymorphism and statin benefits, with a particular focus on their 
pleiotropic cardio and renal protective effects, and especially in higher-risk subsets of 
patients such as among elderly patients undergoing percutaneous coronary 
revascularization, in order to define the best treatment options and improve clinical 
outcome.  
 
